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BACKGROUND
Bone is a unique tissue, capable of self- repair when a small defect exists (1). However, 
when a large defect occurs, for example following injury, trauma or surgery, which exceeds 
the body’s natural capacity for regeneration, surgical intervention is required. Bone is 
one of the most commonly transplanted tissues in the world, with more than 2.2 million 
transplantations performed annually (2).  The current gold standard treatment is use of 
autologous bone grafts (ABG) (3, 4), which are generally well accepted having a success 
rate of around 90% (5, 6). Complication rates have been reported ranging between 8.6% 
(for major incidents) and 20.6% (for minor incidents) (7). Although effective, harvestable 
material is limited and harvesting ABGs can result in donor site morbidity (6), resulting in 
further complications for the patient. ABG alternatives, such as the use of allogeneic or 
xenogenic bone graft material, are associated with other inherent risks such as disease 
transference and immune rejection (8) making them a less desirable treatment option. 
Unfortunately there are no alternatives available which are capable of regenerating 
bone or achieving the level of successful integration with the surrounding host bone as 
demonstrated by ABGs (9), indicating there is a clear and present need for alternative bone 
substitutes. 
Figure 1 : Intramembranous versus endochondral ossification. 
Intramembranous ossification is achieved via the direct 
differentiation of mesenchyme cells to osteoblastic cells resulting 
in bone formation. Endochondral ossification is achieved via 
a cartilaginous intermediate. Mesenchyme cells undergo 
chondrogenic differentiation forming a cartilage template, which 
is remodeled, invaded by blood vessels and ultimately serves as 
the template for future bone formation. Both processes involve the 
release of cytokines/growth factors (green squares) and a bioactive 
matrix (gray) which aid in the recruitment of the nearby vasculature 
and other cells required to achieve bone formation. 
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Through the years scientists have focused on creating biologically relevant cell 
based bone substitutes using mesenchymal stem cells (MSCs). Typically MSC based 
constructs are modelled after one of the developmental pathways of bone formation, 
the intramembranous ossification (IMO) which involves the direct osteoblastic 
differentiation of MSCs, resulting in bone formation (figure 1) . Although such grafts 
have often shown successful bone formation in vitro (10), they often fail due to 
insufficient vascularisation within the construct, resulting in poor integration and 
necrosis in vivo (11, 12). With these limitations in mind, we and others have focused 
on creating tissue engineered grafts which achieve bone formation via endochondral 
ossification (EO). 
DEVELOPMENTAL ENDOCHONDRAL OSSIFICATION 
Unlike IMO, EO is achieved via a cartilage intermediate. During developmental EO, an 
avascular cartilage template, formed via mesenchymal condensation, is establishment. 
This template, often referred to as the cartilage anlagen, is composed of chondrocytes 
at various stages of differentiation (13): the resting, proliferative, and hypertrophic 
zones (figure 2) (13, 14). “Resting chondrocytes” are thought to be essential for 
maintaining longitudinal growth orientation. Resting chondrocytes maintain a specific 
cell population which serves as a source of chondrocyte “stem-cells,” which when 
triggered give rise to proliferative chondrocytes (15-17). Resting chondrocytes help 
inhibit hypertrophic differentiation of proliferative chondrocytes, maintaining them in 
a proliferative state when close to the resting zone border (16, 18, 19). 
The proliferative chondrocytes contribute to longitudinal bone growth (21, 
22). Chondrocyte proliferation is regulated by a complex feedback loop involving 
transforming growth factor-beta (TGF-β), parathyroid hormone-related peptide 
(PTHrP) and Indian hedgehog (Ihh) (22-24). This feedback loop also triggers the 
hypertrophic differentiation of proliferative chondrocytes when appropriate (23). As 
proliferative chondrocytes approach the hypertrophic zone, they will exit the cell cycle 
and undergo hypertrophic differentiation (17, 25). During hypertrophy, chondrocytes 
enlarge and ultimately contribute to longitudinal bone growth (13). During this 
phase the matrix is prepared for calcification. Hypertrophic chondrocytes secrete 
collagen type X (COLX) which accounts for more than 45% of the collagens produced 
during this stage (26). During hypertrophy COLX not only adds structural stability 
to the pericellular network (27, 28) but also helps initiate matrix mineralisation 
via binding with annexin V on matrix vesicles. This binding allows calcium influx 
into vesicles initiating biomineralisation (29-31). At the same time production of 
alkaline phosphatase is increased, ultimately being packaged into matrix vesicles 
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(32, 33). These two events are crucial for the induction of bone formation. Alkaline 
phosphatase plays an essential role in initiating calcification within matrix vesicles, 
ultimately allowing for remodeling to take place (34, 35). 
Figure 2: Chondrocyte zones within growth plate. a) Growth plate of a 4 week old mouse stained with H&E 
shows clearly the different zones of chondrocytes found within the growth plate (adapted from Usami, 2016)
(20). b) Graphical depiction of chondrocyte zones within the growth plate. Resting zone chondrocytes display a 
more sporadic placement, however when proliferation is initiated becomes more elongated in distinct column 
patterns. Hypertrophic chondrocytes are identified by clear cell enlargement. As cells move through the different 
zones they contribute to longitudinal bone growth (adapted from Mgraw Company).
Preparation of the cartilage template for vessel invasion and bone formation
Following initiation of matrix remodeling and mineralization the primary ossification 
center is formed. At the primary ossification center, hypertrophic chondrocytes produce 
angiogenic factors (including VEGF, ANG-1 and PDGRα) which ultimately contribute 
to vascularisation of the cartilage template (36, 37). As the hypertrophic zone and 
primary ossification center is established the perichondrium, a thin homogenous layer 
of mesenchymal cells at the periphery of the template (38), begins to differentiate into 
the periosteum where the first cells which invade the cartilage template originate from 
(14, 39, 40). As the primary ossification center is established mesenchymal cells in the 
perichondrium undergo osteoblastic differentiation, contributing to the formation 
of the bone collar through calcification of the hypertrophic cartilage template prior 
to vascularization (40, 41). The periosteum is an essential source of osteoprogenitor 
cells which will initially invade and ossify the primary ossification center (42). These 
osteoprogenitors in combination with a specific subset of hypertrophic chondrocytes 
(43-45) within the cartilage template and ongoing differentiation of mesenchymal cells 
1
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results in appositional bone growth (46). Once the template has begun to undergo 
mineralisation, matrix remodeling begins to allow for vascular invasion and bone 
formation. 
Release of proteolytic enzymes, including matrix metalloproteinases (MMPs) and 
aggrecanases, initiates matrix degradation localised around hypertrophic chondrocytes 
(47, 48). This degradation releases matrix bound factors including VEGF, MMPs and 
RANKL. While the released MMPs continue to degrade the cartilage template (49-51), 
VEGF (52, 53) and RANKL (54, 55) are important to initiate osteoclast recruitment. Matrix 
remodeling results in glycoaminoglycan (GAGs) degradation within the cartilage template 
(56). This decreases the matrix charge potential allowing vessels to more easily invade 
the cartilage template. This is because  the degradation makes the net charge between 
the matrix and the vessels more neutral allowing for less resistance between the two 
(57). This decreased charge is also beneficial as endothelial cell adhesion is hindered 
in the presence of cartilage proteoglycans and GAGs (56, 58). Simultaneous with matrix 
remodeling, apoptosis of a subset of hypertrophic chondrocytes occurs (40, 59). Together 
these events lead to the formation of vascular channels allowing for vascular invasion of 
the cartilage template (60, 61). 
Vascular invasion and mineralisation of the cartilage template
Angiogenic stimuli produced by hypertrophic chondrocytes and osteoblasts, including 
VEGF, ANG-1, and PDGRα, aid in the recruitment of the nearby vasculature from the 
periosteum (62-64). Vascular invasion of the primary ossification center is the result 
of vascular sprouting from existing capillaries in the bone collar rather than de novo 
synthesised by invading endothelial cells as once thought (65, 66). In fact blood vessels in 
the periosteum initiate vascularisation of the cartilage template and ultimately contribute 
to 70-80% of the overall blood supply to the bone cortex (40, 46, 67). The vascular network 
within developing bone is dense consisting of an interconnected network composed 
of different capillary subtypes which play different roles in maintaining endochondral 
bone during development and aging (68-71). Vascularisation of the cartilage template 
is important as the invading blood vessels bring osteoblasts further into the cartilage 
template further aid in calcification and bone formation (36). 
Pre-osteoblastic precursors move in a pericyte-like fashion into remodeling cartilage 
templates, co-migrating with the invading vasculature ultimately contributing to stabilisation 
of the vascular network and bone formation following vessel invasion (36). Endothelial cells 
further contribute to ossification by secreting BMPs influencing osteoblast cell behavior 
and contributing to the differentiation of mesenchymal cells to osteoblasts (72, 73). 
This bone formation can in part be controlled by the correct zonal distribution of matrix 
vesicles which induce bone formation where found (74, 75). COLX is thought to regulate 
distribution of these matrix vesicles via interactions with annexin V located on the MV outer 
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surface, anchoring them within the hypertrophic zone (76, 77). Annexin V further facilitates 
calcium influx into vesicles which is important for the initiation of mineralisation within 
vesicles, in turn influencing matrix mineralisation and bone formation (75). However, the 
exact role of COLX is still somewhat debated in the field (78, 79) and further research is 
required to determine its exact role. Regardless, as this initial mineralisation begins and 
the matrix is remodeled, and osteoblasts from the bone collar and transdifferentiated 
HC within the cartilage matrix (43) lay down an osteoid matrix on the remaining cartilage 
template (80), maturing within the matrix eventually becoming osteocytes (81). In this way 
bones are formed developmentally during endochondral ossification (figure 3). 
 
Figure 3: Process of endochondral ossification. Following the establishment of the cartilage template, the matrix 
is remodeled, blood vessels invade and bone formation occurs (image modified from beyondachondroplasia.org)
TISSUE ENGINEERED ENDOCHONDRAL OSSIFICATION
Many researchers have shown that endochondral bone formation can be achieved by 
chondrogenically differentiating MSCs in vitro and subcutaneously implanting them in 
vivo (figure 4) (82-86). Unlike TE intramembranous grafts, endochondral TE grafts rely 
on the use of a MSC derived cartilage intermediate to achieve bone formation which 
is advantageous as cartilage is well suited to survive in a hypoxic avascular defect site 
(87). Chondrogenically differentiated MSCs are also capable of inducing the migration of 
nearby vasculature greatly improving construct survival (83, 84, 87). 
In addition to vascularisation, chondrogenic MSCs also trigger the migration of 
osteoclasts and osteoblasts via factors which are both secreted from the construct and 
trapped within the extracellular matrix, including but not limited to VEGF, ANG-1, PDGRα, 
TNF-α, TIMP-1/2 and BMP2 (82, 84, 89). This recruitment initiates matrix remodeling and 
bone formation as seen in the developmental situation (90-92). These constructs are 
1
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quite promising, even being shown in some instances to be capable of bridging large 
bone defects without the need for external biomaterials or growth factors (82-86). What 
is also impressive is that these constructs not only form endochondral bone following 
implantation but also a fully functional marrow cavity (85), highlighting a potential use for 
these constructs in fields outside of tissue engineering. In chapter 2, we review the current 
literature on TE MSC endochondral bone formation. We focus on the role of donor cells 
and extracellular matrix components in orchestrating in vivo EO. We review our current 
understanding of how these grafts have achieved bone formation as well as highlight 
areas others are focusing on to improve TE graft performance.
Figure 4: Achieving tissue engineered endochondral ossification. a) Mesenchymal stem cells (MSCs) are 
expanded to reach required cell number via cell passage. MSCs are then chondrogenically differentiated, usually 
through the addition of TGFβ, dexamethasone and vitamin C (here a chondrogenic pellet is shown in red circle). 
Following differentiation the resulting chondrogenic cells are implanted in an animal model for a predetermined 
period of time.  Following implantation the resulting construct can be retrieved and analysed (constructs in 
white circles) b) Representative MSCs during expansion phase. c) A representative thionine staining of MSCs 
chondrogenically differentiated for 21 days via pellet culture. d) H&E staining showing representative bone formed 
from chondrogenically differentiation MSCs after 8 weeks of subcutaneous implantation in nude mice (B-bone, 
CC-calcified cartilage, BM-bone marrow).
IMPROVING TISSUE ENGINEERED ENDOCHONDRAL BONE FORMATION 
TE MSC mediated bone formation has the potential to one day replace ABG treatment 
options but these constructs are in need of further development in order for this to occur. 
The goal of this thesis was to investigate how we could further improve construction of 
these TE grafts and investigate how we might be able to improve the current approach to 
TE endochondral bone formation to address some real world clinical applications. 
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In chapter 3, we identified and characterised a novel source of paediatric MSCs 
(P-MSCs). These cells compared to adult bone marrow derived MSC (A-MSCs) exhibit 
better expansion characteristics and were found to be a less senescent cell source. Most 
importantly, we found that these P-MSCs were capable of more robust and reproducible 
differentiation which indicate they would be a better cell source of MSC for TE applications. 
In this way we offer researchers an improved cell source option opposed to A-MSCs, the 
current “gold standard” cell source (93, 94). 
In chapter 4, we investigated how an important extracellular matrix component, COLX, 
contributes to chondrogenic differentiation of MSCs and its importance in subsequent 
bone formation. We were able to show when COLX is significantly down regulated it not 
only effected chondrogenic differentiation of MSCs but also how this absence significantly 
hinders in vivo endochondral bone formation. In this way we were able to further improve 
our understanding of how MSC mediated EO is achieved and prove how important COLX 
can be to the process.
In chapter 5, we created a novel micropellet based construct which showed positive 
bone formation in vivo. These micropellets are advantageous as they are small enough 
to be optimised as an injectable bone substitute. With further optimisation these 
micropellets will allow for irregular shaped defects, which require tailor void filling(95) to 
be treated easily by clinicians. These micropellets could be used further in combinational 
approaches as discussed in chapter 6 to further improve TE EO. 
In chapter 6, we characterised the behaviour of MSCs in combination with a 
commercially available enamel matrix derivative (Emdogain (EMD)) used for periodontal 
tissue regeneration, showing EMD did not alter the chondrogenic differentiation of MSCs 
(96, 97). One day it could be possible to use EMD with chondrogenic MSCs to aid in the 
regeneration of soft tissue which is often also damaged around the bone defect site. With 
further development and research this line of work could create an improved construct 
which would potentially allow surgeons to treat both tissue types simultaneously, 
circumventing the need for an additional surgery improving patient treatment and 
recovery.
Our findings are summarised in chapter 7, where we discuss the future perspectives for 
MSC mediated EO. Although just the beginning, this thesis helps better our understanding 
and implementation of MSC mediated endochondral bone. 
1
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Abstract
Endochondral ossification (EO) is the process by which the long bones of the body form 
developmentally and has proven a promising method in tissue engineering to achieve 
cell mediated bone formation. This review focuses on state of the art research pertaining 
to mesenchymal stem cell mediated endochondral bone formation, focusing on the role 
of donor cells, the extracellular matrix and host immune cells during tissue engineered 
bone formation. We highlight possible research avenues to improve graft outcome and 
bone output, as well as emerging research which, when applied to tissue engineered bone 
grafts offers new promise to improve the likelihood such grafts transition from bench side 
to bedside.  
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INTRODUCTION
Bone has an inherent ability to repair itself following small injuries (1), however when a 
critical size defect exists, or is created following surgery, the regenerative capacity of bone 
is exhausted making clinical intervention necessary. As a result bone is one of the most 
commonly transplanted tissues in the world (2). Autologous bone grafts are the current 
“gold standard” treatment option for such defects as they are a natural osteoinductive/
osteoconductive material (3, 4) with low risk of immune rejection (5). Although roughly 
90% of autologous grafts are considered successful (5, 6), their use is limited due to the 
availability of harvestable material, uncertain integration following implantation and risk 
of donor site morbidity (5). Although allogeneic and xenographic grafts are available they 
are associated with other risks, including disease transfer or immunological rejection (7). 
Common complications associated with bone grafts, regardless if they are autologous, 
allogeneic or xenogeneic, include insufficient vascularisation at the implant site leading 
to poor nutrient/oxygen delivery, cell death and core necrosis (3, 4). This highlights a clear 
and present need for new suitable graft alternatives. 
Tissue engineering and regenerative medicine (8) based approaches to bone repair vary 
greatly. Bioactive or inert materials (table 1) are currently being developed, that should 
enhance bone regeneration by guided tissue regeneration. Although promising many of 
these materials and other TERM approaches also rely on the use of iliac crest bone, which 
then does not address the many issues surrounding the use of autologous bone. The use 
of various adult progenitor cells to create cell based alternatives recapitulating on one of 
the developmental pathways of bone formation to achieve bone regeneration and repair 
of critical sized bone defects has received much attention in recent decades. This review 
focuses on the state of the art strategies implemented in cell based TERM and focuses on 
considerations for improved bone regeneration and output. 
CELL BASED STRATEGIES FOR BONE REPAIR; ENDOCHONDRAL VS 
INTRAMEMBRANOUS OSSIFICATION
Bone develops through either intramembranous (9) or endochondral ossification (EO) 
(10, 11). Although both processes vary greatly each results in bone formation. IMO 
involves the direct differentiation of mesenchymal cells to osteoblasts and is how most 
facial bones are formed developmentally (12). IMO can be achieved in TERM by either 
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direct differentiation or through the combination of MSCs with biomaterials (including 
but not limited to tricalcium phosphate or collagen sponges) (13). Although promising, 
this approach has not reached its full potential due to insufficient vascularisation of the 
implant, resulting in core necrosis (13, 14). This vascularisation is crucial for graft survival 
and is required for proper integration with patient’s existing bone. With this in mind, EO is 
a more promising model for bone formation as it naturally induce vascularisation at the 
implant site (15-20). 
Table 1: Bone graft related terminology and definition/examples
Term Definition Ref.
Osteoinductive Material that is able to induce osteogenic differentiation of 
primitive cells; induces bone formation; process that is 
observed during bone repair (healing)
(1, 2)
Osteoconductive Material that causes bone formation on the surface of 
the material; induces migration of bone forming cells to 
surface; observed regularly on bone implants; examples: 
hydroxyapatite, tricalcium phosphate
(1, 2)
Inert material Not chemically active; material does not join/integrate 
directly with bone; example: titanium, steel
(3, 4)
Bioactive material Cause a biological response allowing for tissue bonding 
to material; surface reactivity influences ability to bond to 
bone; example: bioactive glass and ceramics
(5)
Allogeneic graft Tissue or cells obtained from donor material of same 
species as recipient; Osteoinductive and osteoconductive; 
can be fresh or frozen
(4)
Autologous graft Tissue or cells obtained from patient receiving treatment; 
osteoinductive and osteoconductive
(4)
Xenogenic graft Tissue or cells obtained from a non-human source; 
Example: bovine, porcine
(4)
1. Lee JH, editor Development of osteoconductive and osteoinductive bone healing materials. 43rd Annual 
European Calcified Tissue Society Congress; 2016: BioScientifica.
2. Finkemeier CG. Bone-grafting and bone-graft substitutes. JBJS. 2002;84(3):454-64.
3. LeGeros RZ. Calcium phosphate-based osteoinductive materials. Chemical reviews. 2008;108(11):4742-53.
4. Roselló Llabrés X, Roselló Camps À, Jané Salas E, Alburquerque R, Velasco Ortega E, López López J. Graft mate-
rials in oral surgery: revision. Biomimetics, Biomaterials and Tissue Engineering, 2014, vol 19, num 1, p 1-7. 2014.
5. Ducheyne P, Qiu Q. Bioactive ceramics: the effect of surface reactivity on bone formation and bone cell 
function. Biomaterials. 1999;20(23-24):2287-303.
Developmentally, EO relies on the establishment of a cartilage template which is 
achieved via condensation and differentiation of mesenchyme cells (17). Chondrocytes 
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within the template exhibit a zonal distribution, exhibiting clear divisions between 
the different stages of chondrocyte differentiation within the template. Resting 
chondrocytes display a seemingly sporadic distribution and are thought to maintain 
a population of cells which, when triggered, give rise to the more organized, disk 
like proliferating chondrocytes (21, 22). Proliferating chondrocytes contribute to 
longitudinal bone growth and are regulated by a complicated feedback loop which 
includes factors such as TGF-b, PTHrP, and Ihh (23, 24). These factors are also 
involved in initiating hypertrophic differentiation. When hypertrophic differentiation 
starts, chondrocytes secrete factors to recruit other cell types critical for successful 
EO (24, 25) (summarized figure 1). For example factors such as ANG-1, PDGFa, and 
VEGF will aid in the recruitment of the nearby vasculature to the cartilage template 
(26), which will ultimately result in the deliver pre-osteoblastic cells to the cartilage 
template (27). Factors released by the hypertrophic chondrocytes, including MMPs 
and other proteolytic enzymes, will contribute to early matrix remodelling (28) and 
release of RANKL and VEGF will recruit osteoclast cells which further contributes 
to proper matrix remodelling (29). Together osteoblastic cells delivered via the 
invaded vasculature, transdifferentiation of chondrocytes in the cartilage template 
and invading osteoblasts from the surrounding bone collar calcify the cartilage 
matrix and bone formation occurs (27, 30). The coordination of these events 
with cell/vascular recruitment ultimately controls effective bone formation in EO. 
This can be recapitulated in TERM by differentiating MSCs chondrogenically and 
implanted the cells subcutaneously either as pellets or seeded in scaffolds (31-34). 
This seems to mirror developmental EO and shows excellent integration with 
the host (35). Tissue engineered EO utilising mesenchymal stem cells has been 
proven a viable method to achieve bone formation  (36-40). In 2006 Huang et al. 
showed the ability of chondrogenically primed MSCs loaded into a hyaluronan/
gelatin scaffold to form bone (41) and in 2014 van der Stok and Bahney each 
independently demonstrated how these chondrogenic MSCs could also be used to 
partially repair a critical sized defect even without a biomaterial support (34, 42). 
Interestingly, this has been shown to be specific for chondrogenically differentiated 
MSC as chondrocytes following expansion and differentiation will not form bone or 
bone marrow in vivo despite similar culture characteristics. Whether this is to do 
with the developmental origin of these cells or their expression of specific proteins, 
such as Collagen type X (COLX), a hypertrophic associated collagen (which culture 
expanded chondrocytes do not express), is not known (43-45). It is also possible 
that chondrocytes do not interact with cells of the host in a similar fashion. In 
order to develop better TERM approaches to bone defect repair, recapitulating the 
EO process, we must understand how MSC mediated EO occurs and the kinetics 
of the process.
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Figure 1: Snapshot of cellular invasion and behaviour during developmental endochondral ossification. 
Following the establishment of the cartilage template a specific subset of hypertrophic chondrocytes apoptose. This 
creates space for the nearby vasculature to invade and releases bioactive molecules within the matrix. At the same 
time pericytic like pre-osteoblasts invade via passive migration attached to the side of the vasculature. Factors 
released from the degraded extracellular matrix further aid in the recruitment of matrix remodeling osteoclasts. 
The non-apoptotic chondrocytes found within the matrix are capable of transdifferentiation into osteoblast like 
cells which in combination with mature osteoblasts contribute to bone formation.
THE DONOR’S ROLE: RECRUITMENT OF THE HOST AND LONG TERM 
INVOLVEMENT 
The induction of vascular invasion, de novo formation of a marrow cavity and osteoclast 
activity observed in tissue engineered constructs demonstrates endogenous host cells 
have a role in the formation of new bone (46-49). Donor MSCs have been shown to 
directly contribute to the bone forming cell population in TERM EO. Using cell labelling 
methods implanted chondrogenically differentiated MSCs have been shown to persist 
within the bone matrix and contribute directly to bone formation (42, 46, 50). Prior 
research from our lab suggests that the initial bone formation is mediated by donor 
MSCs. Using immunocompetent transgenic rats overexpressing human placental alkaline 
phosphatase (hPLAP), donor cells were tracked following implantation into syngeneic 
wild type rats (46). A mixed population of both positive and negative hPLAP cells found 
embedded within the bone matrix demonstrated that cells were of both donor and host 
origin. Scotti et al. further suggested donor cells which persist in the newly formed bone 
may have undergone transdifferentiation to an osteoblastic like cell. They reported 
that donor and host bone had a zonal distribution. Host cells were found to contribute 
to bone formation at the outer periphery of the implant and donor cells in the central 
portion (50). Although Scotti et al. hypothesise over time these donor cells would be 
replaced with host cells, Bahney and colleagues suggest the majority of bone formation 
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is donor-derived (42). This research is in contrast to the developmental situation where 
it was believed that following hypertrophic differentiation of chondrocytes apoptosis 
was their only fate, as shown in earlier avian based research (51). This theory has been 
challenged as of late. Thanks to studies in development, fracture repair and TERM we 
know hypertrophic chondrocytes do not all apoptose.  Rather, a subset of them are 
actually plastic and capable of transdifferentiating into osteoblasts, or osteoblast like 
cells, further aiding in the process of bone formation (30, 42, 52). Developmentally Yang 
et al. showed these transdifferentiated hypertrophic chondrocytes persisted throughout 
development being present not only in foetal bone but also in the bone of adult mice (30). 
These finds have changed how researchers view bone homeostasis in development and 
in TERM as it is clear chondrocytes do contribute to bone formation. In tissue engineering 
there is a trend towards development of acellular grafts which are indeed attractive from 
a clinical perspective. However, knowing that implanted cells play an important role in 
bone formation, it may be necessary to rethink such approaches in order to maximise 
bone output. Certainly in more challenging clinical situations. 
THE ROLE OF THE EXTRACELLULAR MATRIX IN MSC MEDIATED 
ENDOCHONDRAL OSSIFICATION 
During chondrogenic differentiation of MSCs a bioactive matrix is produced which can 
greatly influence EO in vivo. Studies suggest the quality of the matrix pre-implantation 
influences in vivo bone formation. Scotti et. al reported after longer priming, greater 
chondrogenic induction and glycosaminoglycan (GAG) production was achieved which 
resulted in better bone formation following implantation (32). We also reported how 
stronger chondrogenic induction can influence in vivo bone formation, however we 
hypothesised more GAG rich matrices had delayed marrow formation due to delayed 
remodelling (31). Perhaps this indicates that parameters can be set using extracellular 
matrix (ECM) components produced by chondrogenically differentiated MSCs by which 
to judge bone formation, but to assess this without destruction of the pellet itself would 
be difficult. Recently some have suggested the chondrogenic potential can be influenced 
through the addition of certain FGFs which modulate TGFβ receptors in turn altering 
the GAG concentration (53). If this is the case, researchers could utilise this to alter GAG 
production within the constructs pre-implantation, however research in this area yielded 
conflicting data and how TGFβ receptor modulation influence ECM production by MSCs 
is still an area of ongoing investigation (53, 54). 
When trying to further understand how the ECM influences EO, we can also gain 
valuable insight from researchers that are using chondrogenically differentiated MSCs 
not to achieve EO but to use as a TE cartilage replacement. Chondrocytes formed via 
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differentiation of MSCs compared to “native” chondrocytes exhibit clear differences in 
structure, ECM deposition, cellular phenotypes, and mechanical properties, excellently 
reviewed by Somoza et al. (55, 56).  Researchers are investigating how they can prevent TE 
MSC cartilage constructs from forming bone in vivo. For instance it has been shown how 
suppression of canonical WNT signalling during chondrogenic differentiation resulted in 
less hypertrophic constructs, containing less COLX in the ECM, which had a negative effect 
on bone formation in vivo (57). This may indicate that, for improved bone formation, the 
enhancement of the WNT signalling pathway during chondrogenic differentiation would 
have a beneficial effect on the ECM and cell behaviour for bone repair. Importantly this 
study also highlighted the importance of hypertrophic differentiation for the induction of 
bone formation with MSC based endochondral grafts. 
Developmentally, hypertrophic differentiation precedes mineralisation and during this 
phase 45% of the collagens produced is COLX (58). COLX has been thought to add to the 
structural stability in the surrounding pericellular network of hypertrophic chondrocytes 
(59, 60), but from a bone formation stand point its role can be more clearly seen in 
previous transgenic (Tg) and knock-out (KO) studies. In such studies groups perinatal 
death has been reported in the absence of COLX (around 25% in Tg mice and 10% in 
KO mice) with the surviving mice exhibiting a range of phenotypes including dwarfism, 
skeletal abnormalities, defective haematopoiesis or even phenotypically normal mice 
(61-64). It is initially clear that the absence of COLX has an impact on the normal 
skeletal development in mice, but the exact mechanisms contributing to each of these 
abnormalities needs to be further explored to truly understand how COLX contributes 
to bone formation and the supportive role it plays during the process. Some scientists 
report in the absence of COLX abnormal GAG distribution and decreased heparin 
sulphate proteoglycan (HSPG) content around hypertrophic chondrocytes occurs (62). 
Proper proteoglycan distribution throughout the remodelled matrix is essential as it 
not only plays a role in stabilising the ECM, but also regulates the availability of growth 
factors trapped within the matrix which are crucial for EO, contributing to the induction 
of blood vessel invasion VEGF and the attraction of matrix remodelling cells such as 
osteoclasts in a timely manner(9, 65). Proper ECM arrangement is not only important 
with regard to the above mentioned aspects but also for proper placement of smaller 
structures like matrix vesicles. 
Matrix vesicles are small structures which bud from the membrane of chondrocytes, 
osteoblasts, and other cells. These structures carry with them, among other things, a 
collection of bioactive enzymes, proteins and phospholipids, specific to the cell they are 
produced from, that are important in the initiation of calcification (66, 67). Matrix vesicles 
become entrapped in the ECM and help attract cells via their content (i.e. VEGF to attract 
blood vessels, BMPs to attract osteoblasts, etc.) making their point of anchoring and 
zonal distribution crucial for proper cell recruitment to the correct area (68, 69). There has 
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been research focusing on the interactions between COLX and annexin V binding which 
is found on matrix vesicles. Annexin V facilitates calcium influx into matrix vesicles which 
is important for the initiation of biomineralisation within the vesicles, in turn influences 
matrix mineralisation and bone formation. COLX is able to selectively bind to the annexin 
V, which is hypothesised to initiate this influx of calcium into matrix vesicles (70, 71). 
Others reported that when COLX is absent, vesicle distribution throughout the matrix 
is disrupted and subsequent bone formation is stunted (64, 71). This is alarming and 
shows proper placement of matrix vesicles is required for cell attraction to the proper 
site of bone formation. However this conclusion is challenged by others in the field 
who found that knocking out annexin V resulted in no change in mineralisation or bone 
formation (8). Although initially these results appear to be contradictory there could 
be a simple explanation. As we know, COLX plays a role in supporting and maintaining 
the proteoglycan and collagen organisation of the ECM. When it is absent these are no 
longer organised properly. Matrix vesicles have also been shown to associate with the 
hyaluronic acid binding region found in proteoglycans which can also result in calcium 
influx (71). If COLX is not present it is possible matrix vesicles associate more strongly 
with proteoglycans which would still allow them to be entrapped in the matrix, maybe 
no longer specifically at the border of the chondro-osseous junction, but still able to 
initiate mineralisation, thus allowing bone formation still takes place. 
So far we have seen how COLX can influence bone formation during EO, however, there 
is another important area that is influenced by EO which is the proper development of the 
bone marrow niche, and the area crucial for proper haematopoiesis which studies have 
suggested is also regulated in part by COLX. It has been well established that important 
cytokines, chemokines, and growth factors bind and interact with HSPG which in part 
regulate or control an immune response (71, 72). Researchers have found when COLX is 
decreased there is also a decrease in HSPG and a dysregulation of the immune system of 
Tg mice. There is an increase in factors that play a role in regulating immune responses, 
including IL-4, IL-12, cutaneous T-cell attracting chemokine (CTACK) and leptin which 
have been shown to bind to HSPG, and major changes to the immune system itself. 
Often mice with defective or missing COLX have a severely decreased immune cell 
count. Although the immune cells that remain in the mouse often function properly 
the immune response they illicit cannot be controlled which ultimately has been found 
to lead to death in immune challenge studies (72). When mice with defective/missing 
COLX were challenged with an opportunistic parasite they were initially able to clear the 
parasitic infection but did not recover and ultimately died. Post-mortem investigation 
showed enlarged livers and increased parasite cysts in the brain, liver and lungs both 
indicative of a malfunctioned immune response (72). With a decreased HSPG count and 
an increased production of immune factors the body is unable to regulate the response 
properly. Again here researchers argue over the importance of COLX in regulating 
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the immune response as conflicting results have been shown (64, 73). However the 
differences observed between researchers may also come down to the genetic profile 
of the models they use. 
OSTEOIMMUNOLOGY FROM A TISSUE ENGINEERING PERSPECTIVE
In large bone defects, the cells of the immune system play an important role. The complex 
interaction between cells of the skeletal system and the immune system is critical for 
successful bone repair and is initiated by an inflammatory response to the damaged 
tissue (74-77) (figure 2). This leads to the secretion of pro-inflammatory cytokines, 
including, TNFα, interleukin (IL)-6 and IL-1β (75, 78). These cytokines can induce 
angiogenesis and attract the first cells of the innate immune response (monocytes, 
macrophages, dendritic cells (DCs), neutrophils and natural killer (NK) cells). The innate 
immune cells subsequently release specific cytokines and growth factors which attract 
cells of the adaptive immune system (T and B cells) (79). Immune cells are not the only 
cells attracted during this inflammatory response. Bone-specific growth factors such 
as TGFβ and BMP-2 are also secreted leading to the recruitment of osteoprogenitor 
cells (including MSCs) to the site of inflammation (79). The combined expression of 
growth factors with secretion of inflammatory mediators induces the proliferation and 
differentiation of osteoprogenitor cells to osteoblasts (80-82). IMO and EO are the two 
processes by which osteoprogenitors can differentiate to osteoblasts. Unlike in IMO, 
during EO the secretion of TGFβ2 or 3, BMPs and other signalling molecules leads to 
the formation of a cartilage template that is replaced by woven bone, each of which can 
be influenced by immune cells  (74, 78, 83-85). The majority of fractures heal via EO and 
previous studies have demonstrated the importance of the immune system during the 
repair process; lymphocytes, in particular, have been shown to be crucial for fracture 
healing (1). During bone remodelling, infiltrating T and B cells into the fracture callus 
have been shown to be negatively involved in the bone repair process (86, 87). During 
bone remodelling Th1, Th2 and Treg cells are thought to negatively influence osteoclast 
maturation, however Th17 cells show a positive effect on osteoclast formation (88-90). 
Mice lacking T and B cells appear to have accelerated fracture healing compared to 
those with a fully competent immune system (91). More specifically, CD8 T cells were 
demonstrated to inhibit fracture repair (92), however, other T cells on the other hand 
have varying effects on bone formation/regeneration depending of the subtype that 
was studied (87, 93, 94). Collectively, the complex interaction between the immune 
system and the cells of the skeletal system is critical for the outcome of the bone repair/
regeneration as the manipulation of a specific subset of immune cells could greatly 
impact bone formation.
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Figure  2: T cells can influence osteoblastic and osteclastic maturation. The release of cytokines and various 
growth factures during bone formation and fracture repair results in the recruitment of various immune cells which 
can influence bone formation and remodeling (green arrows-positive influence, red bar lines-negative influence).
The use of autologous cells for bone regeneration are ideal due to the lack of immune 
rejection upon implantation. However, autologous cells have drawbacks in the limited 
quantity of material that can be obtained. Moreover, the material that is obtained is usually 
of poor quality. This is due to the fact that autologous cells are generally obtained from 
elderly and diseased patients and therefore have poor proliferative and differentiation 
capacities compared to those that could be obtained from healthy individuals (95). 
Furthermore, treating a patient with their own cells can cause a major delay in treatment 
timetables due to the in vitro manipulations on the cells (e.g. expansion and quality control) 
before they can be administered back into the patient. Taking this into consideration, new 
and improved TERM-based approaches to bone repair need to be developed. The use 
of allogeneic cells would be preferable as there would be an immediate approved stock 
of cells ready to treat a patient. This advantage has led to an increased interest in the 
research of using allogeneic cells for TERM applications. There has been research already 
on allogeneic MSCs which demonstrate that they are somewhat “immunoevasive” due to 
low surface expression of costimulatory molecules (e.g. CD80 and CD86) and MHC class 
II (96-99). MSCs are known to be immunoevasive which is advantageous as MSCs will be 
implanted into an inflammatory environment during fracture repair (99-109). In normal 
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situations, implantation of allogeneic cells would lead to rejection of the cells by the 
adaptive immune system. However, allogeneic MSCs have be shown to evade the immune 
response and in some instances avoid rejection upon implantation. In studies focused on 
the use of allogeneic MSCs for bone repair, the immune response again played an important 
role in the process. Bone regeneration induced by allogeneic MSCs has been shown to 
be negatively impacted by Th1 T cells through the inhibition of osteogenesis-specific 
gene expression (osteocalcin, Runx2 and ALP) (110). On the other hand, osteogenesis 
was promoted by Th2, Th17 and regulatory T cells (79, 111, 112). While there have been 
numerous studies on allogeneic undifferentiated MSCs, there has been little to investigate 
how the immune system responds to allogeneic MSCs when they are pre-differentiated 
into another tissue type prior to implantation. Allogeneic undifferentiated MSCs have been 
shown to be non-immunogenic (96, 98, 113-115). Due to their immunoevasive nature, 
they can modify the immune system to their desired purpose. Few have investigated the 
effects of allogeneic chondrogenic MSCs on the immune system. Thus far results have 
been conflicting, with reports demonstrating allogeneic chondrogenic MSCs to be both 
immunogenic (116, 117) and non-immunogenic (109, 118-120).
The contradicting results were highly dependent on how the co-culturing work was 
performed during the experiments.  Even in the in vivo setting, little is known about the 
effects of these pre-differentiated MSCs on the immune system. Our group has recently 
detailed the various studies that have focused the interactions between the immune 
system and allogeneic differentiated MSCs in the context of bone tissue engineering (119). 
More recently the “immune privileged” nature of allogeneic MSCs has been called into 
question. As excellently reviewed by Griffin and Lohan, it is well documented that host 
responses vary in response to the presence of allogeneic MSCs from minor inflammation 
to right out rejection (121, 122). 
The idea that allogeneic MSCs could be recognized and targeted by the host is 
concerning for many in the field of tissue engineering. It is clear from these studies that 
there is more research that needs to be conducted to determine how pre-differentiated 
MSCs interact with the immune system in an allogeneic setting before these cells can be 
clinically applicable. It appears increasingly unlikely however that MSCs or differentiated 
MSCs are truly capable of completely evading the immune system. The question to be 
answered is whether or not this is an issue for concern.
FURTHER CONSIDERATIONS, TOWARDS IMPROVED BONE OUTPUT
MSC mediated endochondral bone formation has yielded some promising results in 
animal model defect repair, however treatment of large bone defects is still problematic. 
Although Harada et al. showed how chondrogenically primed rat MSCs could heal a 
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critical sized defect (123) since then no group has demonstrated such large bone defect 
repair. Although MSC mediated EO is capable of forming bone in vivo, the quantity usually 
formed, outside this study, is insufficient to treat large bone defects. From a translational 
perspective the volume of chondrogenic MSCs required to properly heal critical sized 
defects would require unmanageable cell numbers, incubator space, reagents and time to 
maintain which would make the cost of such constructs astronomical (34, 124). In order to 
treat large defects scale-up approaches are necessary to improve bone output.
When considering scaled up bone formation the need for successful vascularisation 
to maintain cell health during regeneration must be taken into account. As most cells of 
the body are rarely more than 100-200µm from a capillary due to diffusion limits which 
influence their behaviour (125, 126), meaning proper vascularisation in TERM constructs 
is critical. Although chondrocytes are thought to be well suited to survive in the initial 
defect site as their true environment is also hypoxic and avascular (127), remodelling, 
vessel invasion and bone formation introduces new cells with variable oxygen/nutrient 
requirements into the defect site (126) making vascularisation crucial to ensure these 
cells’ survival. In small defect repair vascularisation occurs rapidly enough to allow graft 
survival and integration, however with a large defect natural vascularisation rates may 
not be sufficient meaning it must be induced or compensated for in the initial implanted 
construct to prevent cell death. Pre-vascularisation of chondrogenic grafts pre-implantation 
have shown more promising results (128, 129). Freeman et al. showed recently the 
pre-vascularisation of chondrogenic MSC can result in accelerated vascularisation, host 
cell survival and ossification versus non-vascularised counterparts (130). These constructs 
were implanted for only 4 weeks but it would be interesting to see how constructs perform 
following longer in vivo implantation or in an immunocompetent animals. These studies 
are promising but special care must be taken when selecting endothelial cell sources as 
the phenotype of the cell differs between tissue types they are isolated from (131, 132). 
Other groups have investigated how the addition of biologically relevant compounds 
which are known to influence endothelial cell behaviour such as VEGF could be utilised 
to improve graft vascularisation (133). However high doses of VEGF have been shown to 
result in uncontrollable bone formation indicating further research is required to make this 
a more viable option (134). By accelerating processes which are known to be important for 
in vivo bone formation, such as vascularisation, it could be possible to not only improve 
graft performance but also increase bone formation as developmental studies have 
shown that bone forming osteocytes invade the cartilage template via migration with the 
vasculature (134, 135). From a TERM approach prevascularising grafts or inducing faster 
vascularisation is advantageous as you not only tackle the issue of poor vascularisation 
but may also increase bone formation in the process. 
With the complications associated with cell based approaches to tissue regeneration, 
there is a movement in the field to seek out possible cell free approaches which could 
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circumvent these limitations. MSCs used in endochondral TE bone grafts have been shown 
to directly contribute to the bone forming population. As previously discussed it has been 
shown how implanted chondrogenically differentiated MSCs persist within the bone matrix 
and contribute directly to bone formation, instructing host bone formation throughout 
the process (42, 46, 50, 136). These studies suggest implanted cells are essential for proper 
bone formation, however devitalised grafts derived from chondrogenically differentiated 
MSCs have also now been shown to form endochondral bone in vivo (137-140). Martin 
et al. have created decellularised grafts which maintain bone formation potential once 
implanted. This group utilises immortalised cell lines, eliminating many of the culture 
induced issues associated with MSCs, which are decellularised via activation of an 
engineered death inducible receptor within the cells (137-139). Once decellularised and 
implanted these constructs show promising bone formation. What is also interesting is 
the fact that these immortalised cells could be further manipulated to overexpress factors 
which are known to improve bone formation, such as BMP2, which would be incorporated 
in the ECM and could further improve bone output. Kelly et al. following this same line 
of research, showed matrices produces specifically by hypertrophic chondrogenically 
differentiated MSCs produced significantly more bone than non-hypertrophic matrices 
(140) indicating something produced specifically during hypertrophy could be key to 
improved bone formation. Although the bone formed by acellular grafts produced 
significantly less bone volume than cellularised counterparts, these cell free grafts were 
still able to recruit host vasculature and cells required for proper bone formation (137, 
138). With further optimisation they could be a promising alternative to current autologous 
bone grafts. Although decellularised grafts and “off the shelf” treatment options are an 
ideal solution in tissue engineering, the fact remains that cell based approaches as of 
now yield better bone formation than acellular counterparts. As such a popular scale 
up approach is to use growth factors combined with novel biomaterials. Growth factors 
important for developmental induction of EO, such as BMP-2 (124, 141, 142), TGF-β (136, 
142), VEGF (143, 144), PRP (145) as well as potentially novel factors are being characterised 
to determine if their use in combination with mesenchymal stem cells (MSCs) would 
improve bone output. These factors have shown variable results, sometimes performing 
as well as or better than iliac crest bone but sometimes less so (145). Two drawbacks 
associated with this approach are that these factors are extremely expensive and are 
used at supraphysiological levels which is associated with additional risk. For example 
high doses of BMP-2 have been shown to causes soft tissue swelling (146) abnormal 
excessive bone formation (147) and even an increased cancer risk (148) to name a few 
(149). As such researchers are also investigating other compounds which are known to be 
involved in EO which could possibly be used at more physiologically acceptable doses. 
This includes growth and differentiation factor 5 (GDF5). This protein is well known for 
its role in joint formation, chondrogenesis and hypertrophic differentiation and is also a 
   Tissue engineered endochondral ossification
39
member of a subgroup of BMPs (150). Other proteins which are more recently identified 
as being important during EO, including connective tissue growth factor (also known as 
CCN2) and high mobility group box 1 have also been investigated as possible additions 
to improve bone formation as they have shown positive results in vitro for improved 
cell recruitment, vascularisation and osteogenesis (133, 151-153) but could perhaps be 
used at a more physiologically relevant dose compared to BMP2 (154). However even 
when supraphysiological doses are required researchers are looking for ways to possibly 
decrease the effective dosage required to prevent these unwanted side effects. By coupling 
or crosslinking factors to matrices the concentration of these compounds can be reduced 
to something more physiologically acceptable (155, 156). Further research into the 
identification of new biologically relevant compounds is also useful. Recent studies have 
identified new stem cell populations which activates in response to acute skeletal injury 
(157). By studying the secreted profile of these cells in comparison with controls perhaps 
new relevant targets could be identified which may not even require supraphysiological 
doses to be effective. Additionally the use of “organs-on-a-chip” and other computational 
models, which have been proven promising methods to identify/validate targets and for 
improved screening methods (158), could accelerate results and research. 
CONCLUSIONS
Modelling grafts in TE after EO has been an active area of research in bone TE for years. 
The initial cartilage graft is well suited to survive in an avascular environment and it is 
capable of inducing the migration of all the previously mentioned cell types on its own. 
Although it has been shown to be a reproducible method of bone formation, progress 
to enhance the bone forming capacity of these constructs in order to properly fill large 
bone defects has been slow moving. However as our understanding of the interactions 
that take place improve, not only between donor and host cells but also those of a fully 
functioning immune system we will better understand how to improve our grafts. As 
research in the field continues we will be able to improve graft vascularisation, integration 
and bone output making these tissue-engineered endochondral grafts a viable alternative 
to autologous bone graft substitutes in the future.
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Abstract
Mesenchymal stem cells/marrow stromal cells (MSCs) are attractive for applications 
ranging from research and development to use in clinical therapeutics. However, the 
most commonly studied MSCs, adult bone marrow MSCs (A-MSCs), are limited by 
significant donor variation resulting in inconsistent expansion rates and multilineage 
differentiation capabilities. We have recently obtained permission to isolate paediatric 
MSCs (P-MSCs) from surplus iliac crest bone chips. Here, we developed a simple and easily 
replicable isolation protocol yielding P-MSCs which adhere to MSC defining guidelines. 
After confirming immunophenotypic marker expression we compared expansion rates, 
senescence, morphology and trilineage differentiation of P-MSCs to A-MSCs for multiple 
donors. We found P-MSCs have faster in vitro replication, consistently show significantly 
lower senescence and are capable of more reproducible multilineage differentiation 
than A-MSCs. We therefore believe P-MSCs are a promising candidate for use in research 
applications and potentially as part of an allogeneic therapeutic treatment.  
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INTRODUCTION
Over the last decades interest in mesenchymal stem cells/marrow stromal cells (MSCs) 
has grown; many have recognised their potential to advance scientific discovery 
and improve clinical treatment options (1-3). MSCs unlike other lineage-committed 
progenitors or terminally differentiated cells are capable of multilineage differentiation 
which is desirable for a number of applications ranging from developmental research 
to use in advanced therapeutic medicinal products (ATMPs) (4-7). MSCs are attractive 
for these applications as they can be easily isolated, cultured and expanded in vitro (2, 
8). They have been found in a variety of tissues, blood and even urine (9-11). Regardless 
of their point of isolation, MSCs must adhere to criteria determined by the International 
Society for Cellular Therapy (ISCT) as outlined by M. Dominici et al. (12). Briefly, cells must 
(i) be plastic adherent, (ii) retain their multipotent differentiation capacity and (iii) express 
a panel of surface antigens. Although a diverse variety of MSCs meet these criteria, there 
are still numerous differences between populations depending on the method and tissue 
they are isolated from including variability in in vitro expansion, differentiation capability 
and cell surface marker expression (8, 13-16). These differences and the inherent donor 
variation observed between MSCs makes clinical translation and their use in ATMPs 
challenging.
In order for MSCs to be used as part of AMTPs, a sufficient quantity of cells must 
be obtained which are capable of producing consistent outcomes that satisfy the 
regulatory requirements set by the European Medicines Agency (EMA) and the Food and 
Drug Administration (FDA) (17-19). When removed from the environment of their in vivo 
niche and expanded in vitro, MSCs rapidly lose their ability to replicate and differentiate, 
meaning their characteristics change unpredictably over time in culture (16, 20-22). This 
variation is often observed in bone marrow (BM) MSC populations which as of now is still 
considered the gold standard when it comes to MSCs (23, 24). Other MSC sources such 
as umbilical cord and adipose tissue are being actively characterised with promising but 
conflicting results (11, 25-27). An ideal MSC source would allow isolation with minimal 
patient discomfort and yield cells capable of reproducibly meeting EMA/FDA regulatory 
requirements (28). Although BM MSCs are currently the gold standard for MSCs their 
isolation is associated with a painful procedure and harvesting of such material results in 
substantial patient discomfort and recovery time when used (27, 29). Many researchers, 
us among them, use surplus clinical material obtained from patients undergoing surgical 
procedures (total hip or knee replacement for example). However the age and disease 
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status of the donors often negatively influences MSC performance (20). Kretlow et al. 
found cell attachment, proliferation and differentiation were all affected as donor age 
increased (30, 31). MSCs from aged donors were less capable of secreting and maintaining 
a chondrogenic matrix (32), and had a decreased bone forming potential in vivo (33). It 
has also been reported cells from the elderly often exhibit cellular dysregulation Which 
negatively impacts stem cell populations (31, 34, 35). Additionally MSCs from elderly 
patients have been shown to have age-induced gene expression changes and earlier 
replicative senescence which further negatively effects MSC performance (31, 36). 
Cellular dysregulation in aging populations has also been hypothesised to add to the 
pathogenesis of these diseases which results in a damaged stem cell population (31, 
34). As neither cell dysregulation or senescence is useful for research or the clinics, MSCs 
isolated from adult or geriatric populations are not an ideal cell source. MSCs isolated 
from younger patients have shown promise (11). 
Recently we have gained access to small quantities of surplus bone from paediatric 
patients undergoing craniofacial reconstruction surgery from which we can easily isolate 
paediatric MSCs (P-MSCs). The resulting MSCs are plastic adherent, maintain MSC related 
immunophenotype and are capable of consistent differentiation. Here we outline how 
these cells are obtained, isolated and cultured as well as describe the morphological 
and phenotypic characteristics of these novel MSCs to allow others in the scientific 
community to utilise them for their own applications. We compare P-MSCs to adult MSCs 
(A-MSCs) isolated from BM and find P-MSCs to be capable of more consistent multilineage 
differentiation. We believe P-MSCs to be a promising candidate for use in both research 
as well as clinical applications.
MATERIALS AND METHODS
Mesenchymal stem cell isolation and expansion
All samples were harvested with the approval of the medical ethics committee at Erasmus 
Medical Centre (ErasmusMC, Netherlands). Adult-MSCs were isolated and expanded as 
previously described (MEC-2004-142 & MEC-2015-644) (13). Paediatric mesenchymal 
stem cells (P-MSC) were isolated from leftover iliac crest bone chip material obtained 
from patients undergoing cleft palate reconstructive surgery (MEC-2014-16; 9-13 years). 
P-MSCs were isolated by gently swirling 10mL of expansion medium (αMEM containing 
10 % serum (lot # 41Q204K, Gibco), 50 mg/mL gentamycin, 1.5 mg/mL fungizone, 25 µg/
mL L-ascorbic acid 2-phosphate and 1 ng/mL fibroblast growth factor-2 (Instruchemie)) 
with iliac crest bone chips. Medium was removed and the process was repeated with an 
additional 10 mL expansion medium. The cell suspension from the combined medium of 
both washes was plated in a T75 flask and iliac crest chips were processed for histology. 
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Flasks were washed 24 hours after plating with PBS to remove non- adherent cells and 
debris. Cells were cultured at 37°C and 5% carbon dioxide (CO₂). Expansion medium 
was refreshed twice a week. P-MSCs were passed at approximately 80-90% confluency 
using 0.05% trypsin and replated at approximately 2,300 cells/cm2. After passages 2-4 
A-MSCs were used for trilineage differentiation and after passage 5 for FACs analysis, 
immunocharacterisation and b-galactosidase stainings. P-MSCs were always used after 
passage 5 unless otherwise noted (b-galactosidase staining, passage 8).
FACS analysis 
A-MSCs and P-MSCs were trypsinised at passage 5 and rinsed in FACS flow. Cells were 
incubated for 30 minutes in 100 μL FACS buffer (BD Biosciences) containing antibodies 
against CD90 (APC), CD105 (FITC), CD73 (PE), CD271 (APC), CD166 (PE), HLA-DR (PerCP), 
HLA-ABC (FITC) or CD45 (PerCP). MSCs were washed with FACS flow, centrifuged at 689 
g for 5 minutes, resuspended in 200 μL of FACS flow and analysed on a FACS Jazz flow 
cytometer (all antibodies BD Biosciences). Post-analysis was completed using FlowJo 
software version 10.0.7 (Treestar Inc.).
 
Senescence staining and quantification
The percentage of senescent cells was determined by staining for senescence-associated 
lysosomal β-galactosidase using a modification of Debacq-Chainiaux et al’s protocol 
(37). A-MSCs and P-MSCs were seeded at 2,300 cells/cm2 in complete expansion medium 
(as described above). On day 3 cells were refreshed and after 6 days cells were fixed 
in 1% [v/v] formaldehyde (Sigma) and 0.5% glutaraldehyde [v/v] (Sigma) in PBS for 15 
minutes at 4°C. After washing with distilled water, cells were incubated for 24 hours at 
37°C with 250 μL/cm2 staining solution (1 mg X-gal (5-bromo-4-chloro-3-indolyl-β-D-ga-
lactopyranoside (Roche Diagnostics), 1.64 mg potassium hexacyanoferrate (III) (Sigma), 
2.1 mg potassium hexacyanoferrate (II) trihydrate (Sigma), 2 μmol magnesium chloride 
hexahydrate (Sigma), 150 μmol sodium chloride, 7.3 μmol monohydrous citric acid 
(Sigma), 25.3 μmol disbasic dodium phosphate dihydrate (Sigma)) per mL distilled water; 
pH 6.0). After rinsing in distilled water, cells were counterstained with 1 g/L neutral red 
(Sigma) in a solution of 0.2% acetic acid. The number of positive cells was quantified and 
plotted relative to total cell number.
Chondrogenic differentiation
2x105 A-MSCs or P-MSCs were suspended in 500 mL of chondrogenic medium 
(high-glucose DMEM supplemented with 50 µg/mL gentamycin (Invitrogen), 1.5 µg/mL 
fungizone (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 40 µg/mL proline (Sigma), 
1:100 v/v insulin-transferrin-selenium (ITS+; BD Biosciences), 10 ng/mL transforming 
growth factor β3 (Peprotech), 25 µg/mL L-ascorbic acid 2-phosphate (Sigma), and 100 
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nM dexamethasone (Sigma)) in 15 mL polypropylene tubes. Samples were centrifuged at 200 
g for 8 minutes. Medium was replaced twice weekly for 21 days (P-MSCs) or for 28-35 days 
(A-MSCs). Samples were formalin fixed for histology (4% (w/v) formaldehyde in PBS for 2 hrs). 
Osteogenic differentiation
A-MSCs or P-MSCs were plated at a density of 3x103 cells/cm2 in expansion medium 
(previously described). 24 hours following seeding medium was replaced with 
osteogenic induction medium (high-glucose DMEM supplemented with 10% serum, 50 
mg/mL gentamycin, 1.5 mg/mL fungizone, 10 mM glycerol phosphate (Sigma), 0.1 mM 
dexamethasone (Sigma), and 0.1 mM L-ascorbic acid 2-phosphate (Sigma)). Medium was 
refreshed as previously described for 14-21 days, depending on when cell sheets began to 
pull away from the outer perimeter of the well or when calcium deposition was observed 
macroscopically, at which point the culture was ended. Cells were cultured at 37°C and 
5% CO₂. Samples were prepared for histology (fixed in 70% EtOH at 4ºC) following the 
end of culture. 
Adipogenic differentiation
A-MSCs or P-MSCs were plated at a density of 2.1x104 cells/cm2 in adipogenic induction 
medium (high-glucose DMEM supplemented with 10 % serum, 50 mg/mL gentamycin, 
1.5 mg/mL fungizone, 0.2 mM indomethacin (Sigma), 0.01 mg/mL insulin (Sigma), 0.5 mM 
3 iso-butyl-1-methyl-xanthine (Sigma)). Medium was refreshed as previously described 
and cells were maintained at 37°C and 5% CO₂. Samples were prepared for histology 
(fixed in 4% (w/v) formalin) following harvest.
Haematoxylin-eosin staining
Paediatric bone chips were fixed for 24 hours in 4% (w/v) formalin, decalcified in 10% 
EDTA (w/v) for 30 days and paraffin embedded. Chondrogenic MSC pellets were fixed 
in 4% (w/v) formalin for 2 hours and paraffin embedded. 6 mm-thick sections were 
cut, deparaffinised and stained with haematoxylin-eosin (H&E). H&E staining was 
performed by incubating deparrafinised samples in Gill’s haematoxylin (Sigma) for 5 
minutes, washed in none distilled water for 5 minutes, washed in distilled water, and 
counterstained for 45 seconds with 2% Eosin (Merck; in 50% ethanol, 0.5% acetic acid). 
Samples were fixed in 70% EtOH for 10 seconds and rehydrated (sequentially in 96% 
EtOH, 100% EtOH, and xylene for 1 minute). Samples were mounted in Entellan (Depex). 
Thionine staining
Deparaffinised samples were incubated in 0.04% thionine (prepared in 0.01M sodium 
acetate, pH 4.5) for 5 minutes, differentiated in 70% EtOH for 10 seconds and then 
rehydrated as previously described. Samples were mounted in Entellan (Depex). 
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von Kossa staining 
Osteogenically differentiated MSCs were fixed in 4% (w/v) formalin for 1 hour. Following 
a rinse with ultrapure water, samples were incubated in 5% w/v silver nitrate (Sigma) 
for approximately 30 minutes under direct light provided by a light box. Following 
incubation samples were washed in ultrapure water and counterstained with nuclear 
fast red (Merck) for five minutes. Samples were dehydrated in 70% EtOH for 10 seconds 
followed by 96% EtOH and 100% EtOH for one minute. Samples were imaged in 100% 
EtOH directly following staining. 
Oil red staining 
Following a 15 minute fixation in 4% (w/v) formalin samples were rinsed in distilled water 
for 10 minutes. 0.5% w/v Oil-red O (in 2-propanol; Sigma) was added to samples for 10 
minutes followed by further rinsing with distilled water. Samples were imaged in distilled 
water. 
P-MSC-PBMCs co-culture
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats from healthy 
male donors (Sanquin, Rotterdam) by a Ficoll-Paque PLUS gradient separation as 
previously described (GE Healthcare) (38). PBMCs were resuspended in human serum 
conditioned medium (HCM) (RPMI-1640 medium, 1% GlutaMAX (Life Technologies), 
50 µg/mL gentamycin, 1.5 µg/mL fungizone, 10% human serum (Sigma-Aldrich)) and 
stored at -80ºC until use. P-MSCs were trypsinised as previously described and seeded in 
low-evaporation round bottom 96 well plates. 24 hours following seeding, 1x107 PBMCs 
were labelled with 20 µL of CFSE. T cells were stimulated by adding anti-CD3/CD28 
antibodies (1 µL/106 cells) to PBMC suspension with an anti- goat linker antibody (2 µl/106 
cells). Stimulated 100,000 PBMCs were co-cultured with P-MSCs at a P-MSC:PBMC ratios 
of 1:2.5, 1:5, 1:10 or 1:20., PBMCs were harvested 5 days later and stained with CD3-PerCP 
(clone SK7), CD8- PE-Cy7 and CD4-APC (BD Biosciences). Samples were fixed in 3.6% 
paraformaldehyde and analysed using a FACS Jazz flow cytometer (BD Biosciences) and 
post-analysis was completed using FlowJo software version 10.0.7 (Treestar Inc.). Data is 
represented as reciprocal of the mean fluorescence intensity (MFI). 
Statistical analysis
Mann Whitney U analysis was performed using SPSS (Ver 21. SPSS Inc, Chicago, USA) on 
data used in figures 1, 2, and 3. Kruskal-Wallis analysis with Dunn’s multiple comparison 
was performed on figure 4. Data are shown as mean ± SD, P-values under 0.05 were 
considered significant.
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RESULTS 
Paediatric MSCs express a panel of established MSC cell surface markers
P-MSCs were isolated from small quantities of surplus bone biopsies from patients 
undergoing cleft pallet reconstruction surgery. The environment from which the P-MSCs 
are isolated contains both bone and bone marrow elements (figure 1).
Donor 1 Donor 2 Donor 3 Donor 4
100 mm
Figure 1: P-MSCs are isolated from illiac crest rest material containing both bone and bone marrow. Hematoxylin 
and Eosin stained sections of the illiac crest chips from which P-MSCs are isolated. The cell source environment is 
rich in both bone marrow elements and bone (black arrows indicate bone, white arrow bone marrow).
In order to prove isolated cells were indeed true MSCs we characterised the 
immunophenotypic expression of common MSC markers. These markers included a panel 
which are known to be expressed on MSCs including CD105, CD90, CD73, CD271, CD166 
and HLA-ABC as well as a commonly used negative marker, lymphocyte associated CD45 
(12, 39). Both A-MSCs and P-MSCs were analysed following 5 passages. MSC markers were 
expressed at a similar level in P-MSCs and A-MSCs (figure 2). 
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Figure 2: P-MSCs and A-MSCs express similar levels of general stem cell markers. General MSC related markers 
which are commonly expressed on A-MSCs (A) are also expressed at a similar level in P-MSCs (B) (N.S. differences 
between A-MSCs and P-MSCs; Mann Whitney U test) Both populations are negative for haematopoietic marker CD45 
however are positive for a panel of other immune related markers. 
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Both populations were negative for CD45, and positive HLA-ABC. About half the 
P-MSCs and A-MSCs population were positive for HLA-DR which was not surprising as 
HLA-DR expression can increase with in vitro culture of MSCs (40). We found no significant 
difference in HLA-DR expression between P-MSCs and A-MSCs (figure 2).
Paediatric MSCs have enhanced expansion properties compared to adult MSCs
During expansion P-MSCs exhibit a typical MSC morphology similar to that observed 
in A-MSCs (figure 3a). Although the total number of days A-MSCs and P-MSCs took to 
establish the initial culture (figure 3b) and reach passage 3 (figure 3c) did not change, 
P-MSCs expanded significantly faster than A-MSCs, yielding more cells after the same time 
in culture (figure 3d; p<0.02). This difference in cell number could be attributed to cell size. 
A-MSCs enlarged the longer they were in culture, whereas P-MSCs remained small (figure 
3a, 4a). 
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Figure 3: P-MSCs and A-MSCs have a similar rate of expansion but P-MSCs undergo more population doublings. 
A) Cell morphology typically observed during expansion of P-MSCs (representative donor). B) Total days taken to 
establish culture from plating initial cell suspension to passage 0 does not differ between P-MSCs and A-MSCs. 
C) Expansion time from passage 0 to passage 3 does not differ between A-MSCs and P-MSCs. D) Total number of 
population doublings between passage 1 and passage 3 is greater in P-MSCs compared to A-MSCs (p<0.0238; Mann 
Whitney U test). (Abbreviations: CFU-colony forming units; P0: passage 0;P1: passage 1; P2: passage 2; P3: passage 
3; PD: population doublings) 
P-MSCs are a less senescent cell source compared to A-MSCs
As increased cell size is a hallmark of senescence, a permanent cell cycle arrest that 
A-MSCs have been shown to undergo in vitro, we compared senescence between A-MSCs 
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and P-MSCs  (41, 42) We observed cell enlargement of A-MSCs compared to P-MSCs (figure 
4a). Senescence-associated lysosomal β-galactosidase staining showed P-MSCs, even 
after extensive passage (p8; figure 4b, c), contained significantly less senescent cells than 
A-MSCs at an earlier passage (p5; figure 4b, c).
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Figure 4: P-MSCs contain significantly less senescent cells than A-MSCs. A) Cell morphology observed during 
expansion of P-MSCs (p8) and of A-MSCs (p5). A-MSCs display a larger cell morphology compared to P-MSCs even 
though they are an earlier passage. Both A-MSCs and P-MSCs were seeded at the 2,300 cells/cm2 and expanded 
under normal conditions for 6 days. B) b-galactosidase staining of both P-MSCs (p8) and A-MSCs (p5). P-MSCs 
contain far less positively b-galactosidase stained cells than A-MSCs. C) Percentage of senescent cells counted in 
P-MSCs is significantly lower than that of A-MSCs (n=4; p<0.000; Mann Whitney test). (Abbreviations: P5: passage 5, 
P8: passage 8) 
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In monolayer P-MSCs reduce T cell proliferation at a similar level as A-MSCs
Our lab has previously shown that A-MSCs repress the proliferation of allogeneic T cells, 
a feature essential for many anti-inflammatory MSC-based therapeutics (38). To examine 
if P-MSCs repress T cell proliferation, allogeneic T cells from PBMC fractions were CD3/
CD28 stimulated and added in suspension to P-MSC monolayers. In both CD4+ and CD8+ 
T cell subsets, P-MSCs inhibited T cell proliferation in a dose-dependent manner and to 
similar extend as we have previously reported for A-MSCs (figure 5). Here we found P-MSCs 
exhibited a similar level of inhibition to what was reported by A-MSCs (38).
Figure 5: P-MSCs reduce allogeneic CD4+ and CD8+ T cell proliferation in monolayer. Stimulated (+CD3/
CD28) PBMCs co-cultured with P-MSCs at different MSC:PBMC ratios (1:2.5, 1:5, 1:10, 1:20). CD4+ (A) and CD8+ (B) 
proliferation rates were found to decrease in a dose dependent manner following 5 days in culture. (N=3 P-MSC 
donors N=2 PBMC donors) Abbreviation: MFI-mean fluorescent intensity. (Kruskal-Wallis with Dunn’s post hoc 
correction; ***P>0.001, *P>0.05)
Paediatric MSCs exhibit more consistent multilineage differentiation capacity 
compared to adult donors 
A-MSCs are known to exhibit inconsistent differentiation capabilities which varies greatly 
between donors. This severely limits their use in applications where consistency is essential 
(43). Compared to A-MSCs donors (passages 2-5; figure 6a) the trilineage differentiation 
potential of P-MSCs (passage 5; figure 6b) was found to be more consistent. Even though 
P-MSCs were used several passages beyond that used for the A-MSCs, P-MSCs more 
consistently underwent adipogenesis, osteogenesis and chondrogenesis with only 1 
out of 12 donors not being able to make bone or cartilage following treatment (figure 
6b). A-MSCs showed much more variability in their differentiation potential. Out of the 
14 A-MSC donors tested, 3 donors failed to undergo adipogenesis, 5 donors failed to 
osteogenically differentiate and 5 donors were unable to chondrogenically differentiate 
(figure 6a). 
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Figure 6: P-MSCs show more consistent capacity for multilineage differentiation. A) A-MSCs (passage 2-4) show 
great variation in differentiation capacity. A-MSCs are known to exhibit far greater variation in differentiation 
capacity (Chamberlain, Fox et al. 2007; Noort, Scherjon et al. 2003). B) P-MSCs (passage 5-6) are capable of 
tri-lineage differentiation with all donors but one being capable of osteogenic and chondrogenic differentiation. All 
P-MSCs tested could adipogenically differentiation. 
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DISCUSSION
Identifying cell sources with enhanced and reliable differentiation capabilities and 
expansion properties is necessary in order for MSCs to be more readily utilised both in 
research and in ATMPs. Here we have established a simple isolation protocol to obtain 
P-MSCs from surplus iliac crest bone chip material (figure 1). We confirmed P-MSCs 
expressed cell surface markers typically used to properly identify MSC populations. 
P-MSCs showed similar expression levels of general stem cell markers CD105, CD90, CD73 
and CD166 compared to A-MSCs, as well as the absence of the hematopoietic marker 
CD45 (figure 2). As these markers are conventionally used to identify MSCs (44, 45) we are 
confident that this marker expression in combination with other results presented here we 
have proved P-MSCs are indeed MSCs. In this study A-MSCs displayed a higher expression 
of CD271 and HLA-DR compared to P-MSCs. It has been previously reported that in MSCs 
CD271 as well as HLA-DR expression decrease over time in culture (46, 47). As P-MSCs 
undergo more population doublings compared to A-MSCs at the same passage (figure 
3d) this increased cellular division could have contributed to the decreased expression of 
both CD271 and HLA-DR we observe in P-MSCs.
P-MSCs expanded more rapidly than A-MSC donors, which might be attributed to 
the relatively low senescence in P-MSCs (figure 4). Senescent cells are much larger than 
non-senescent cells (48). A-MSCs have more enlarged senescent cells which do not divide 
(49, 50) making it easy to understand why the population doublings in A-MSCs are effected. 
Additionally, by preventing proliferation, senescence can also blocks differentiation 
pathways requiring proliferation, such as chondrogenic differentiation (51). Being able to 
obtain cells with higher proliferation and differentiation capacity in a shorter time than is 
possible with A-MSCs makes P-MSCs an attractive cell source. 
If P-MSCs are to be utilised in an allogeneic setting it is important to show P-MSCs 
maintain immunomodulatory capabilities typically observed in A-MSCs (38, 52). MSCs 
are known to be able to manipulate T-cell proliferation and phenotypic behaviour and 
their immunosuppressive nature makes them an interesting candidate from a clinical 
perspective (52-54). In this study we found P-MSCs were capable of inhibiting T-cell 
proliferation at a similar level to what we previously reported with A-MSCs using a 1:5 ratio 
(MSC:PBMCs) (38). For use in an allogenic model it is advantageous for P-MSCs to inhibit 
T-cell proliferation to prevent an unwanted immune reaction following transplantation. 
However how P-MSCs interact with other immune cell types including antigen presenting 
cells needs to be determined in order to further understand how they would respond to a 
fully functional immune system. 
A-MSCs have been reported to have inconsistent multilineage differentiation capabilities 
(15, 20, 55). P-MSCs were capable of more consistent multilineage differentiation compared 
to the A-MSCs in this study. Senescence could have contributed in part to the difference 
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we observed here as senescent MSC cell populations undergo phenotypic changes (56, 
57) and exhibit chromosomal abnormalities (58, 59) which ultimately could influence 
their differentiation capacity (51). In this study it is plausible that a combination of factors 
influenced the differentiation capacity of these cell populations. It is logical cells from a 
younger, healthier patient which contain less senescent cells would be capable of better 
multilineage differentiation than senescent cells obtained from elderly patients. Having 
a cell source with more consistent differentiation capacities is ideal as it allows for more 
reproducible results. 
Here we have described an easy isolation protocol which allows access to a P-MSC 
population with enhanced expansive and differentiation potential compared to 
A-MSCs. P-MSCs with their rapid expansion, low senescence and consistent multilineage 
differentiation are therefore prime candidates for applications from drug screening and 
development to use in ATMPs.
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Abstract
With limited autologous and donor bone graft availability, there is an increasing need for 
alternative graft substitutes. We have previously shown that chondrogenically priming 
mesenchymal stem cell pellets for 28 days in vitro will reproducibly result in endochondral 
bone formation after in vivo implantation. However, pellet priming time is quite extensive 
for clinical applications. A micropellet (μpellet)-fibrin construct was developed and coupled 
with a decreased priming period determined by an in vitro time course experiment. In vitro 
data showed expression of chondrogenic genes and matrix production after 7 days of 
chondrogenic priming, indicating briefer priming could possibly be used to induce bone 
formation in vivo. Both 7 and 28 day primed pellet, pellet-fibrin and μpellet-fibrin constructs 
were cultured for in vitro analysis and implanted subcutaneously into nude mice for 8 
weeks. μpellet-fibrin constructs cultured in vitro for 7 or 28 days showed comparable bone 
to standard pellets in vivo. MSC mediated bone formation was achieved following only 7 
days in vitro priming. Bone formation in vivo appeared to be influenced by overall matrix 
production pre-implantation. Given this short priming time and the injectable nature of 
the μpellet-fibrin constructs this approach might be further developed as an injectable 
bone substitute leading to a minimally invasive treatment option which would allow for 
tailored filling of bone defects.
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INTRODUCTION
 
Autologous graft material for reconstruction of large bone defects is limited and as 
harvesting is associated with additional patient risk and discomfort there is an increasing 
need for suitable graft alternatives (1-3).
“Developmental engineering,” mimicking the processes of tissue development and 
healing to create biologically relevant replacements for congenitally missing, worn out 
or damaged tissues, is commonly implemented in bone tissue engineering to develop 
replacements for autologous grafts (4, 5). Bone formation predominantly proceeds via two 
mechanisms, intramembranous (IO) and endochondral ossification (EO), both of which 
are exploited for bone graft development using stem cells and other cell types with varying 
degrees of success (6-9). Although the IO route of bone formation is often used in tissue 
engineering (TE), grafts often exhibit poor survival due to insufficient vascularisation and 
perfusion following implantation (10). For these reasons this work  focused on achieving 
tissue engineered bone via the EO pathway.
Endochondral bone formation relies on a cartilage intermediate (11, 12). Mesenchymal 
cells condense, undergo chondrogenic differentiation, leading to the production of a 
cartilage template rich in collagens, glycosaminoglycans (GAGs), and bioactive signalling 
molecules (13, 14). As the process continues the chondrogenic matrix is calcified and 
degraded which results in the release of these molecules (14-16), triggering cell migration, 
blood vessel invasion, and ultimately bone formation (3, 17-19). It has previously been 
shown that EO can be mimicked to achieve bone formation using chondrogenically 
primed MSC pellets (20, 21). Chondrogenically differentiated MSC pellets in vitro for 
28 days results in vascularised, endochondral bone when subcutaneously implanted 
in vivo for 8 weeks. This approach to TE bone formation is advantageous as cartilage is 
better suited to survive in the initial avascular environment and naturally promotes 
the revascularisation of the graft material when implanted into defect sites (22). Whilst 
a promising approach to bone regeneration, hurdles remain when trying to implement 
such techniques clinically. A major obstacle is the lengthy in vitro priming time required 
to differentiate pellets to stimulate endochondral ossification in vivo, a process which is 
essential as undifferentiated MSC pellets typically fail to form bone or form an insufficient 
quantity to heal defects (21). It has recently been shown in vitro priming can be reduced 
to 14 days, however, it has not been investigated whether further reduction is possible 
to allow for swifter patient treatment (23). In vitro priming time is further compounded 
by the fact that inherent differences between MSC donors results in variable degrees of 
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chondrogenic differentiation which can affect the quantity and quality of bone produced 
in vivo (21, 24, 25). In order for these constructs to be clinically relevant criteria for in vitro 
differentiation which is shown to lead to reproducible bone formation must be identified. 
However in vitro priming and donor variation are not the only obstacle between these 
constructs and clinical translation. Isolation of MSCs from bone marrow requires a painful 
surgical procedure and there would always be a secondary surgical procedure following 
the construction of MSC pellets required for graft implantation to treat the defect. The 
development of an injectable bone substitute would allow for a less invasive treatment 
option and possibly decreased recovery.
To address these issues we have created chondrogenically primed constructs comprised 
of micropellets (µpellets) suspended within a fibrin hydrogel. This approach exploits the 
reproducible and swift bone forming capacity of MSC pellets coupled with a shorter in 
vitro priming time to decrease the time required pre-implantation. μpellet constructs are 
promising in that their small size allows them to pass easily through a needle making 
them ideal for an injectable therapy. This would allow clinicians to properly fill a defect 
site without the need of a tailor printed/designed implant to fit specific void shapes and 
would result in decreased patient discomfort and possibly recovery time. 
In this study we aimed to examine the bone forming potential of these μpellet constructs. 
We investigated decreased in vitro priming with the goal of achieving bone formation in a 
shorter period of time than has been reported. Additionally we observe how differences 
in chondrogenic potential pre-implantation influence endochondral bone formed in vivo. 
METHODS AND MATERIALS
MSC isolation  
Human bone marrow MSCs were isolated from 3 separate consenting patients undergoing 
total hip arthroplasty (Medical Ethical Testing Commission (METC) approval code 
2004-142; donor 1: female, 60; donor 2: male, 34; donor 3: male, 58) and expanded in 
αMEM containing 10 % FBS serum (lot # 41Q204K, Gibco; Bleiswijk, Netherlands; 50 µg/
mL gentamycin, 1.5 µg/mL fungizone, 25 µg/mL L-ascorbic acid 2-phosphate and 1 ng/
ml fibroblast growth factor-2 (all from Instruchemie, Delfzijl, Netherlands). Heparinised 
bone marrow aspirates were taken from the greater trochanter and plated at 30-100 x10⁶ 
nucleated cells per T175 flask (Corning; Amsterdam, Netherlands). 24h after plating, flasks 
were washed and refreshed to remove non adherent cells and debris. Cells were cultured 
at 37°C and 5% carbon dioxide (CO₂) and medium was refreshed twice a week. MSCs were 
passed at 85-90% using 0.05% trypsin (Gibco; Bleiswijk, Netherlands) and replated at 
approximately 2,800 cells/cm2, cells were expanded to passage 4 at which time they were 
chondrogenically differentiated. 
   Micropellet mediated endochondral ossification
105
Chondrogenic differentiation
2x105 MSCs were suspended in complete chondrogenic medium (high-glucose DMEM 
supplemented with 50 µg/mL gentamycin (Invitrogen; Landsmeer, Netherlands), 1.5 µg/
mL fungizone (Invitrogen; Landsmeer, Netherlands), 1mM sodium pyruvate (Invitrogen; 
Landsmeer, Netherlands), 40 µg/mL proline (Sigma; Zwijndrecht, Netherlands), 1:100 
v/v insulin-transferrin-selenium (ITS+; BD Biosciences; Temse, Beligum), 10ng/mL 
transforming growth factor β3 (Peprotech; London, UK), 25 µg/mL L-ascorbic acid 
2-phosphate (Sigma; Zwijndrecht, Netherlands), and 100 nM dexamethasone (Sigma; 
Zwijndrecht, Netherlands)) in 15 mL polypropylene tubes and centrifuged at 200g for 
8min to create standard pellets. To generate µpellets, 3x106 MSCs per well were seeded in 
Aggrewell™800 plates (StemCell Technologies; Evergem, Belgium)  in 1 mL chondrogenic 
medium and centrifuged at 300g for 10 min and incubated overnight creating 300 µpellets 
(10,000 cells per pellet) per well. Following 24h of incubation µpellets were transferred 
to 24 well plates (Corning; Zwijndrecht, Netherlands) or fibrin encapsulated. Cells 
undergoing chondrogenic differentiation were cultured at a ratio of 4x105 cells/mL of 
complete chondrogenic medium. All conditions were cultured at 37°C in 5% CO₂. 
Chondrogenic time course 
MSCs (donor information above) were chondrogenically differentiated via standard pellet 
culture conditions as described. Samples were harvested for histology following 2, 5, 7, 10, 
14, and 28 days of differentiation. Samples were fixed in 4% (w/v) formaldehyde in PBS for 
2h. Samples for biochemical assays were harvested after 7, 14, 21, and 28 days. Samples 
were digested overnight at 60ºC in buffer containing papain (0.2M NaH₂PO₄, 0.01M 
EDTA2H₂O, 0.01M cysteine HCl, 250 µg/mL papain (Sigma; Zwijndrecht, Netherlands), 
pH 6) and stored at -20ºC until processed. Samples for gene expression analysis were 
harvested after 2, 5, 7, 10, and 14 days of chondrogenic differentiation. Samples were 
homogenised in 350 µL trizol (Gibco; Bleiswijk, Netherlands) and stored at -80ºC until 
processed.
Fibrin encapsulation
Pellets and µpellets were collected 24h post pelleting and suspended in 100 µL human 
fibrinogen (40 mg/mL dissolved in 0.9% NaCl; Sigma; Zwijndrecht, Netherlands) at a 
density of 60 µpellets or 3 standard pellets per 100 µL fibrinogen. Human thrombin (Sigma; 
Zwijndrecht, Netherlands) was added at a ratio of 0.5 IU to 1 mg fibrinogen, crosslinking 
took between 15-20min. Samples for implantation and in vitro analysis were maintained 
in complete chondrogenic medium supplemented with 0.0875IU/mL bovine aprotinin 
(Sigma; Zwijndrecht, Netherlands) for 7 or 28 days to slow the degradation of the fibrin 
material by cell constructs during in vitro culture. All medium was refreshed twice a week 
and maintained in 5% CO₂ at 37°C.
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Subcutaneous implantation
All experiments were approved by the Animal Experiments Committee at the Erasmus 
Medical Centre, Rotterdam (DEC protocol 116-12-08). 3 loose pellets, 60 loose µpellets, 
3 fibrin encapsulated pellets, and 60 fibrin encapsulated µpellets (600,000 cells total 
per pocket) were implanted subcutaneously in 10 (7 day in vitro primed samples) 
or 13 week-old (28 day in vitro primed samples) male athymic nude mice (Balb/c 
nudes, Charles River; Sulzfeld, Germany), which were housed in groups of three 
under standard light dark cycles with access to ad libitum food and water (18 mice in 
total). Pre-operatively animals were given pain medication (buprenorphine 0.05mg/kg 
bodyweight) under general anaesthesia (1-3.5% isoflurane). Two incisions were created 
dorsally (one between the shoulder blades and the other between the hip bones) per 
animal, with two subcutaneous pockets created per incision. One of the following 
conditions: 3 standard pellets, 3 standard pellets encapsulated in fibrin, 60 loose 
µpellets, or 60 µpellets encapsulated in fibrin, were implanted per pocket (implantation 
randomised between pockets and animals). 3 replicates per condition were implanted 
per MSC donor (3 MSC donors total). Eight weeks post implantation, animals were 
euthanised by CO₂ asphyxiation and constructs were retrieved. 
Micro CT imaging
µCT scans were performed and reconstructed at the Applied Molecular Imaging 
Erasmus MC facility using the Quantum FX (Perkin-Elmer; Groningen, Netherlands). Ex 
vivo scans were acquired using a field of view of 10mm (90kV/160mA, 3min). Scans were 
quantified using Analyze 11.0 software (AnalyzeDirect; Nieuwe Niedorp, Netherlands). 
Calcified tissue was quantified by converting original linear attenuation coefficient 
measurements, by linear transformation, to Hounsfield units (HU). Global thresholding 
was applied to all scans and determined by visual inspection. Values over 400HU, 
corresponding to 0.133g/cm3 (as determined by phantom scans), were segmented out 
and independently quantified as calcified tissue. 
Histology 
Samples were fixed in 4% (w/v) formaldehyde in PBS for 2h (in vitro) or 24 h (in vivo) 
and in vivo samples were decalcified in 10% w/v EDTA in PBS for 7 to 10 days refreshing 
every other day then paraffin embedded. 6 µm-thick sections were cut, deparaffinised 
and stained with haematoxylin-eosin (H&E), safranin O, or tartrate-resistant acid 
phosphatase (TRAP). 4-5 sections were used per sample. H&E staining was performed 
by incubating deparaffinised samples in 100% Gil’s haematoxylin (Sigma; Zwijndrecht, 
Netherlands) for 5min followed by 7min incubation in non-distilled water. After 
washing with distilled water samples were incubated in 2% Eosin (Merck; Amsterdam, 
Netherlands;  in 50% ethanol, 0.5% acetic acid) for 45sec, 70% ethanol for 10sec, then 
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rehydrated (100% ethanol for 1min, xylene for 1min) and mounted. H&E stained sections 
were used to quantify the percent of bone, calcified cartilage, and bone marrow using 
morphologically characteristics to determine boundaries. Aforementioned areas were 
segmented and then quantified using Image J (National Institute of Health; Maryland, 
USA). Safranin O staining was performed by incubating deparaffinised samples in 
0.05% light green solution (in distilled water; Sigma ; Zwijndrecht, Netherlands) for 
8min followed by a rinse in 1% acetic acid (in distilled water; Fluka; Zwijndrecht, 
Netherlands) and a 12min incubation in 0.1% Safranin O solution (in distilled water; 
Fluka; Zwijndrecht, Netherlands). Samples were then rinsed with 96% ethanol for 30sec, 
rehydrated (as previously mentioned) and mounted. TRAP staining was performed by 
incubating deparaffinised samples in 0.2M acetate buffer (0.2M sodium acetate (Sigma; 
Zwijndrecht, Netherlands), 100 nM L (+) tartaric acid (Acros; Antwerp, Belgium); pH 5) for 
20min. Following incubation 0.5 mg/ml naphtol AS-BI phosphate (Sigma; Zwijndrecht, 
Netherlands) and 1.1 mg/ml fast red TR salt (Sigma; Zwijndrecht, Netherlands) was 
added to the acetate buffer and incubated for 1hr at 37ºC. Collagen type II samples 
were rinsed in distilled water and counterstained with haematoxylin as previously 
described.
Immunohistochemistry
Samples were prepared as previously described (26). Briefly, Collagen type II stained 
samples were incubated in 1mg/ml pronase (Sigma; Zwijndrecht, Netherlands) and 
10mg/ml hyaluronidase (Sigma; Zwijndrecht, Netherlands) for 30min at 37ºC. 10% 
normal goat serum (Southern Biotech; Uithoorn, Netherlands) was used to block 
non-specific antibody binding. Sections were incubated with 0.4mg/ml collagen type II 
antibody (II-II/II6B3; Developmental Studies Hybridoma Bank, University of Iowa; Iowa 
City, USA). Collagen type X staining was performed by incubating samples with 0.1% 
pepsin (Sigma; Zwijndrecht, Netherlands) in 0.5 M acetic acid (pH 2.0) followed by 10mg/
ml hyaluronidase treatment. Rat knees which were decalcified in 10% EDTA (w/v in 
distilled water; Sigma; Zwijndrecht, Netherlands) for 2 weeks. Sections were incubated 
with 1: 10 or 1:100 diluted collagen type X antibody (in PBS/1%BSA; X53;Quartett; 
Berlin, Germany) for 16hr. All stainings were incubated with 2.2 mg/ml biotin-SP F 
(ab) 2 goat-α-mouse (diluted in PBS/1%BSA; Jackson; Huissen, Netherlands) for 30min 
and washed in PBS. Samples were then incubated with streptavidin-AP for 30min 
and washed in PBS (diluted 1:50 in PBS/1%BSA; Biogenex; Uithoorn; Netherlands) 
All slides were incubated 0.2 M Tris-HCL substrate (pH 8.5; containing 1g/25ml Neu 
Fuchsin (in 2M HCl ;1B467, Fisher Scientific; Landsmeer; Netherlands;), NaNO2 (4% in 
distilled water; Sigma; Zwijndrecht, Netherlands), 0.3mg/ml Naphtol AS-MX phosphate 
(Sigma; Zwijndrecht, Netherlands), 33 µl/ml Dimethylformamide (Sigma; Zwijndrecht, 
Netherlands), 0.25 mg/ml Levamisole (Sigma; Zwijndrecht, Netherlands) for 30min. 
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Collagen type II samples were rinsed in PBS followed by haematoxylin counterstaining. 
Matching mouse IgG1 (X0931; Dako; Amstelveen, Netherlands) isotype controls were 
performed for each staining. 
Biochemical assays 
Samples were digested overnight at 60ºC in buffer containing papain (as described above). 
Glycosaminoglycan (GAG) content was quantified using a dimethylmethylene blue (DMB, 
pH 3; Sigma; Zwijndrecht, Netherlands) assay. Chondroitin sulphate C (Sigma; Zwijndrecht, 
Netherlands) was used to create a standard for this experiment and A530:A590 ratio was 
used to determine GAG content. DNA was quantified from papain digested samples using 
ethidium bromide with calf thymus DNA (Sigma; Zwijndrecht, Netherlands) as a standard. 
Gene expression
Samples were homogenised in 350 µ trizol (Gibco; Bleiswijk, Netherlands; Bleiswijk, 
Netherlands). 70 µl 100% chloroform was added and samples were agitated, incubated 
for 10min at room temperature, and the aqueous phase was transferred to Rneasy® kit 
columns. RNA was purified using RNeasy® microkit (Qiagen; Venlo, Netherlands) and 
cDNA was reverse transcribed using a First Strand cDNA Synthesis Kit (RevertAid; Bleiswijk, 
Netherlands; MBI Fermentas; St. Leon-Rot, Germany) as per manufactures instructions. 
Real-time PCR was performed using 10ng of cDNA. Samples were amplified using 
either SYBR Green I dye (Eurogentec; Seraing, Belgium) or TAQman 2xReagent (Applied 
Biosystems; Nieuwerkerk a/d Ijssel, Netherlands) in 10 µL PCR mix reactions containing 10 
µM forward and reverse primers for GAPDH, ColII, ColX, COLI, VEGF, MMP13 or BMP2 (Table 
1) for a maximum of 40 cycles. For gene expression analysis 3 different MSC donors were 
analysed with three pellets per donor. Genes are expressed as delta CT.
Primer Name Forward sequence (5’- 3’) Reverse sequence (5’- 3’)
GAPDH ATGGGGAAGGTGAAGGTCG TAAAAGCAGCCCTGGTGACC
VEGFa CTTGCCTTGCTGCTCTACC CACACAGGATGGCTTGAAG
COLI CAGCCGCTTCACCTACAGC TTTTGTATTCAATCACTGTCTTGCC
COLII CCCCATCTGCCCAACTGA CTCCTTTCTGTCCCTTTGGT
COLX ACTTCTCTTACCACATACACG CCAGGTAGCCCTTGATGATGTACT
BMP2 AACACTGTGCGCAGCTTCC CTCCGGGTTGTTTTCCCAC
MMP13 AAGGAGCATGGCGACTTCT TGGCCCAGGAGGAAAAGC
Abbreviations: GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; VEGFa, Vascular endothelial growth factor a; 
COLI, Collagen type I; COLII, Collagen type II; COLX, Collagen type X; BMP2, Bone morphogenetic protein 2; MMP13, 
Matrix metallopeptidase 13 
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RESULTS
MSCs display chondrogenic characteristics during the first week of in vitro 
priming
The effects of in vitro chondrogenic priming time were investigated in order to determine 
the earliest stable chondrogenic induction time which could be utilised for in vivo bone 
formation studies. Time course experiments, in which MSC pellets were differentiated 
for 2, 5, 7, 10, 14, 21 or 28 days showed GAGs were present early during priming and 
increased greatly by 7 days of in vitro culture compared to earlier time points (figure 1a, 
b). Increased expression of chondrogenic genes including ColII and ColX was observed 
by 7 days and continued to rise thereafter compared to time point 0 (figure 1c). As 
chondrogenic characteristics were observed to be stably and reproducibly increased 
compared to earlier time points after 7 days of in vitro priming we chose to continue with 
this time point during in vivo studies. 
Figure 1: Chondrogenic markers are upregulated after 7 days of in vitro priming. (a) Safranin O staining (donor 
1) and (b) GAG (corrected for DNA) results show increase in matrix GAG deposition after 7 days of culture (all 3 MSC 
donors, 3 pellets per donor). (c) Expression of ColII and ColX increased after 7 days of in vitro culture and continued 
to increase over time (all 3 MSC donors, 3 pellets per donor; graphs display mean and standard deviation).
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µpellet-fibrin constructs maintain chondrogenic potential compared to standard 
pellets
µpellets were constructed using roughly 10,000 cells per µpellet, 20 of these µpellets 
were equivalent to the cell density of our standard pellet which is typically utilised in 
tissue engineered EO studies. µpellets were encapsulated in a 40 mg/ml fibrin gel. 
To ensure fibrin was not inhibiting chondrogenesis pellets were also encapsulated 
for comparison. Pellets, pellet-fibrin, µpellets and µpellet-fibrin were cultured for 
either 7 or 28 days after which time they were harvested for in vitro analysis or 
subcutaneously implanted in nude mice. In vitro, µpellets on their own failed to 
chondrogenically differentiate after 7 or 28 days, fibrin encapsulation was necessary 
in order to achieve differentiation (figure 2). In donor 3, µpellets aggregated following 
prolonged culture (28 days) forming one pellet with a decreased chondrogenic 
potential to standard pellets cultured from the same donor (figure 2c). Safranin O 
staining suggest a similarity in proteoglycan content between pellet, pellet-fibrin and 
µpellet-fibrin constructs after either 7 or 28 days of priming as staining intensity is 
comparable between conditions, although in earlier primed samples it may appear 
the µpellet-fibrin condition is less intense, the pellets are spread over a larger area 
distributing the staining over the section.  The cumulative staining is similar to 
that observed in the standard pellet culture. Between donors there is variation in 
staining intensity highlighting a degree of donor variability during chondrogenesis 
(figure 2). 
Cell morphology for each donor is similar between conditions and time points 
(figure 3a) but after 7 days of culture GAG/DNA data for donor 2 shows that 
µpellet-fibrin constructs contained more GAG than pellet counterparts (3b; one 
donor 6 replicates). This difference is not observed after extended culture (figure 
3c; one donor 6 replicates).
Expression of COLII, COLX and COLI was observed in all donors after either 7 
or 28 days of in vitro culture however gene expression levels varied significantly 
between donors (figure 4). Samples collected from donor 1 after both 7 and 28 
days of culture showed greater expression and staining of COLII (figure 4a; 5). COLX 
expression was higher in µpellet-fibrin compared to pellets alone at both 7 and 
28 days (figure 4b). Fibrin encapsulation appeared to lead to a more intense COLII 
staining (figure 5) throughout the matrix after 7 or 28 days of culture as shown in 
immunohistochemistry. There was no clear difference in COLX protein expression 
between conditions (figure 6). In IgG control stainings, COLX appeared to slightly 
stain the fibrin material (figure 6 inserts in a). This background staining was far less 
intense than that observed within our constructs. Staining specificity shown in rat 
knee tissue, however the optimal staining concentration for rat tissue was found to 
be lower than that of human (figure 6d). 
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Figure 2: Non-encapsulated µpellets failed to chondrogenically differentiate. Safranin O results show 
non-encapsulated µpellets exhibit no matrix GAG deposition after 7 or 28 days of culture (donors 1 (a) and 
2 (b)) whereas other constructs show positive staining. Donor 3 (c) µpellets aggregated forming one pellet 
after 28 days in culture. 
5
Chapter  5  | 
112
Figure 3: µpellet-fibrin constructs maintain cell morphology and exhibit chondrogenic potential. H&E staining 
showing morphology of chondrogenic pellet, pellet-fibrin and µpellet-fibrin (donor 2) is comparable between 
conditioned after 7 and 28 days of differentiated.
  .
  
Figure 4: Matrix components differentially affected between donors, however, hypertrophic marker COLX is 
consistently upregulated in µpellet-fibrin constructs cultured for 28 days. Expression of (a) ColII, (b) ColX and (c) 
ColI in pellet, pellet-fibrin and µpellet-fibrin constructs after 7 or 28 days of in vitro chondrogenic culture. Hypertrophic 
associated gene COLX was upregulated between pellet and µpellet-fibrin conditions cultured for 28 days.
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Figure 5: µpellet-fibrin constructs exhibit more homogenous collagen type II distribution after longer 
priming. COLII immunohistochemistry on chondrogenically differentiated  pellet, pellet-fibrin and 
µpellet-fibrin constructs after 7 and 28 days of in vitro culture from MSC (a) donor 1, (b) donor 2 and (c) 
donor 3 (d) IgG controls performon donor 1 day 28 samples.
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Figure 6: µpellet-fibrin constructs exhibit more homogenous collagen type X distribution after longer priming. 
COLX immunohistochemistry on chondrogenically differentiated pellet, pellet-fibrin and µpellet-fibrin constructs 
after 7 and 28 days of in vitro culture from (a) donor 1, (b) donor 2 and (c) donor 3. (d) IgG controls are of day 28 
samples from donor 1. (e) Rat knee positive control at 1:10 and1:100.
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µpellet-fibrin conditions generally had lower gene expression of VEGF compared 
to pellet controls after 7 days of in vitro culture, an effect that was not observed after 
28 days of culturing (figure 7). In donor 1, VEGF expression was slightlydownregulated 
when compared to donors 2 and 3 after 28 days in culture (figure 7a). Other secreted 
factors including BMP2 and MMP13 were differentially affected between conditions 
and donors, but were present in all samples. Downscaling the standard pellet to 
µpellet-fibrin format did not appear to hinder the expression of these markers 
(figure 7).
Figure 7: Gene expression of secreted factors is differentially affected across donors and is maintained in 
µpellet-fibrin constructs. Expression of (a) VEGF, (b) MMP13 and (c) BMP-2 in pellet, pellet-fibrin and µpellet-fibrin 
constructs after  7 or 28 days of in vitro chondrogenic culture. Hypertrophic associated gene BMP2 was upregulated 
between pellet and µpellet-fibrin conditions in some donors where as it was relatively unaffected in others. Other 
markers were differentially affected depending on the donor.
5
Chapter  5  | 
116
7 days of in vitro chondrogenic priming results in tissue calcification in vivo 
In addition to in vitro characterisation pellets, pellet-fibrin, µpellets and µpellet-fibrin 
constructs were subcutaneously implanted in nude mice for 8 weeks and harvested 
for volumetric analysis and histology (figure 8a). Non-encapsulated µpellets could 
not be located following implantation and thus could not be analysed. Between 
the two in vitro priming times, 7 or 28 days, there was significantly more calcified 
tissue present in conditions primed for 28 days in vitro as shown in the µCT 
(figure 8 b, c). Fibrin encapsulation of pellets lead to greater calcification in vivo 
than standard pellets for all donors cultured for 7 days (figure 8c) however fibrin 
encapsulation does not appear to affect calcification when constructs are cultured 
for 28 days. Pellets that were not encapsulated in fibrin were only retrievable from 
1 donor after implantation following 7 days of in vitro culture, and for this donor 
only 1 pellet was often retrieved of the 3 implanted. Regardless of the donor 7 day 
primed pellet-fibrin and µpellet-fibrin constructs were always retrieved and always 
showed calcification on µCT after in vivo implantation (figure 8b, c). 28 primed 
pellets, pellet-fibrin and µpellet-fibrin constructs were consistently retrieved from 
donors 1, 2 and 3 and always showed comparable calcification between donors 
(figure 8b, c). In some donors as shown in the µCT image (figure 8) pellets or 
µpellets had merged forming one larger construct. This was observed within some 
fibrin encapsulated samples only and was not observed consistently with a specific 
donor, priming time or condition. 
Bone formation in vivo is dependent on extracellular matrix quality 
pre-implantation 
Bone and calcified cartilage were observed in all harvested samples. Calcified 
tissue was quantified by µCT (figure 8), however non-encapsulated pellets primed 
in vitro for 7 days could only be retrieved from donor 1 and the quantity of bone 
and calcified cartilage observed at the time of harvest in H&E sections varied 
between donors. Donor 1 had a denser GAG rich matrix pre-implantation and 
higher COLII and COLX expression/production (figure 2, 4, 5, 6) which resulted in an 
almost complete absence of bone marrow and only a small recruitment of matrix 
remodelling osteoclasts after 8 weeks in vivo (figure 9-11) compared to donor 2 
and 3 that had a less GAG rich matrix pre-implantation and lower COLII and COLX 
expression/production (figure 2, 4, 5, 6). This resulted in a greater percentage of 
bone marrow elements and greater osteoclast recruitment after in vivo implantation 
for the same time (figure 9, 10, 12, 13). These differences are observed most clearly 
in the histological sections as it was not possible to segment out calcified cartilage 
from bone in the µCT. 
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Figure 8: 7 day primed samples and µpellet constructs form mineralised tissue after in vivo implantation (a) 
In vivo study outline (b) µCT scans of constructs primed in vitro for 7 or 28 days after 8 weeks in vivo implantation. 
(Donor 1; white bar indicates same length in all µCT images for scale). (c) Volume of mineralised tissue obtained 
from ex vivo µCT scans shows donor related differences in mineralisation.
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Figure 9: Quantity of bone and bone marrow following 7 days of in vitro priming is donor dependent. Percentage 
of bone, bone marrow, calcified cartilage and other tissue (not bone, bone marrow, or calcified cartilage) found in 
samples primed in vitro for 7 days following 8 weeks in vivo. Quantification for (a) pellets, (b) pellet-fibrin and (c) 
µpellet-fibrin (3 constructs per condition per donor; 3 MSC donors used) was completed using high magnification 
images of H&E staining and segmenting areas based on morphology in ImageJ.
   Micropellet mediated endochondral ossification
119
Figure 10: Quantity of bone and bone marrow following 7 days of in vitro priming is donor dependent. Percentage 
of bone, bone marrow, calcified cartilage and other tissue (not bone, bone marrow, or calcified cartilage) found in 
samples primed in vitro for 28 days following 8 weeks in vivo. Quantification for (a) pellets, (b) pellet-fibrin and (c) 
µpellet-fibrin (3 constructs per condition per donor; 3 MSC donors used) was completed using high magnification 
images of H&E staining and segmenting areas based on morphology in ImageJ.
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Figure 11: High GAG density 
in vitro results in slower 
remodeling and bone formation 
in vivo. (a) Day 7 and (b) 28 in 
vivo H&E and TRAP staining for 
donor 1. The intensity of the 
safranin O staining (figure 2) 
showed the quantity of GAGs is 
high pre-implantation. Denser 
GAG-rich matrices appear to 
be harder for cells to penetrate 
as evident by a decrease 
in marrow formation and 
osteoclast infiltration. (In H&E 
stains CC = calcified cartilage, 
BM = bone marrow, B = bone 
marrow; in TRAP staining arrows 
indicate areas of TRAP positivity).
Figure 12: GAG density in vitro 
affects the rate of remodeling 
and bone formation in vivo. 
(a) Day 7 and (b) 28 in vivo 
H&E and TRAP staining for 
donor 2. The intensity of the 
safranin O staining (figure 2) 
showed a moderate quantity 
of GAGs pre-implantation. In 
vivo there was a varying degree 
of calcification, marrow space 
development and osteoclast 
infiltration which appeared 
correlated to in vitro GAG 
deposition pre-implantation. 
(In H&E stains CC = calcified 
cartilage, BM = bone marrow, B 
= bone marrow; in TRAP staining 
arrows indicate areas of TRAP 
positivity).
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Figure 13: Lower GAG density in 
vitro results accelerated 
remodeling and bone formation 
in vivo. (a) Day 7 and (b) 28 in 
vivo H&E and TRAP staining for 
donor 3. The intensity of the 
safranin O staining (figure 2) 
showed the quantity of GAGs is 
low pre-implantation. Less dense 
GAG-rich matrices appear to be 
easier for cells to penetrate as 
evident by a increased in marrow 
formation and osteoclast 
infiltration. (In H&E stains CC 
=calcified cartilage, BM = bone 
marrow, B = bone marrow; in 
TRAP staining arrows indicate 
areas of TRAP positivity).
DISCUSSION
Priming time and reproducible bone formation represent two of the major hurdles for 
translation of tissue engineering based approaches to the clinic. In this manuscript we 
demonstrate that 7 day chondrogenic priming coupled with encapsulation in a fibrin gel is 
sufficient to allow bone formation to take place in vivo. Following 7 days of in vitro priming 
pellets reproducibly produced a more chondrogenic GAG rich matrix from the earlier 
priming times. At this time point hypertrophic markers were also consistently upregulated 
from the original starting time point. However, without encapsulation only one donor was 
observed to calcify in vivo after being primed for 7 days in vitro. This donor produced no 
bone marrow elements. Given the lack of bone formation the chondrogenic markers we 
chose are most likely insufficient predictors of in vivo bone formation.
Novel µpellet-fibrin constructs were created and characterised to ensure downscaling 
the standard pellet culture to a µpellet format would not inhibit chondrogenesis and 
subsequent bone formation. We observed that µpellet-fibrin constructs showed equivalent 
matrix production and bone formation compared to standard pellet culture counterparts. 
In a recent predictive model it was shown that matrix deposition and collagen distribution 
tends to accumulate around the outer periphery of pellets where nutrient supply is 
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abundant (27). They predict that uniform distribution of proteoglycans and collagens 
could be maintained be decreasing pellet size which would make nutrients and factors 
more available to individual differentiating cells. This could indeed explain why we saw 
an increase in some matrix related genes in µpellet constructs. Decreased VEGF gene 
expression after 7 days of culture in µpellet-fibrin constructs compared to standard pellets 
was also observed, but this decrease was not observed after 28 days of in vitro priming and 
did not appear to hinder in vivo bone forming capacity in µpellet-fibrin constructs. 
In vivo results confirmed bone formation can be achieved by chondrogenically priming 
constructs for only 7 days in vitro using either standard or µpellet-fibrin constructs. 
Non-encapsulated µpellet constructs failed to differentiate in all donors and time 
points except for non-encapsulated µpellets cultured for 28 days from donor 3. These 
non-encapsulated µpellets aggregated forming one pellet after 28 days of culture. This 
aggregated pellet and all other non-encapsulated µpellets that were implanted did not 
result in bone formation indicating that µpellets alone and aggregated µpellets are not 
capable of bone formation. It appears that µpellets require encapsulation during in 
vitro differentiation or during implantation in order for bone formation to be achieved. 
We observed that fibrin encapsulation increased bone formation when priming time 
was reduced to 7 days in subcutaneously implanted pellet constructs. 7 day non-fibrin 
encapsulated pellets were rarely retrieved (one in three donors) and all retrieved pellets 
lacked bone marrow elements. Given the lack of bone formation it is probable that other 
chondrogenic markers may more accurately predict in vivo bone formation than the ones 
we had selected. It is possible that pellets that did not calcify or form bone were simply 
absorbed by the host or perhaps the addition of fibrin prevented this absorption long 
enough for remodelling and bone formation to take place. 
Often fibrin encapsulated samples exhibited fusion in vivo, resulting in a fused mass 
of pellets/µpellets versus individual pellets on the µCT.  This fusion was not consistently 
observed between conditions or donors but was only observed in fibrin encapsulated 
conditions. It could be the fibrin contracted bringing the pellets in closer proximity 
allowing for this fusion to take place. Fibrin has been shown to reduce oxygen diffusion and 
tension, leading to a hypoxic environment (28). This hypoxic environment is favourable for 
bone formation and has been shown to increase osteoclast and osteoblast activity.This 
may explain how fibrin was able to enhance bone formation in vivo (29-31). However in a 
prior pilot study, pellets primed in vitro for 7 days in the absence of fibrin did form bone 
containing mature marrow cavities (data not shown). This highlights a degree of variability 
in graft performance based on inherent donor differences which have been previously 
reported (1, 21). Indeed in this study we observed major differences between donors 
influenced the degree of bone formation observed following implantation.
In our study we observed a difference in chondrogenic differentiation and subsequent 
bone formation between all three donors. Samples retrieved from donor 1 often lacked 
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bone marrow elements following implantation. In vitro analysis from donor 1 showed a 
decrease in both VEGF, and COLX gene expression compared to the other two donors. 
VEGF is known to be involved in vascularisation which means this decreased expression of 
VEGF could have attributed to the lack of bone marrow elements we observed following 
in vivo implantation (32). Additionally, donor 1 showed greater COLII expression and 
GAG accumulation as well as decreased COLX gene expression compared to donors 
2 and 3. Histologically we observed that GAG and other matrix collagens production 
pre-implantation appeared to be related to bone formation in vivo. A denser matrix 
containing more collagen elements and GAGs resulted in less mature bone formation, 
more incomplete remodelled calcified cartilage and a decrease in the presence of matrix 
remodelling osteoclasts. These differences are best observed in the H&E stained sections, 
as the µCT quantifies the entire area of calcified tissues and would not be able to show 
quantities of bone versus calcified cartilage. We hypothesise that denser matrices takes 
longer to be remodelled in vivo, as vessel and cell invasion is more difficult in a dense 
environment which results in delayed bone formation, whereas a less dense matrix can 
be invaded more easily, leading to faster vascularisation and remodelling, thus resulting 
in quicker bone formation. It has previously been shown that GAG depletion of articular 
cartilage leads to an increase in blood vessel invasion which contributes to osteoarthritis 
and bone development in diseased cartilage, which supports our hypothesis (33, 34). 
However, we also hypothesise that a minimum level matrix production is necessary for 
bone formation to occur and to prevent pellets from being resorbed or lost in vivo as 
evidenced by the fact that 7 day primed pellets that had extremely low levels of GAG 
production pre-implantation were unable to be retrieved (donor 2 & 3). It is difficult to say 
that variation in matrix elements alone attributed to the difference we observed in bone 
formation. In order to properly investigate this a larger number of donors needs to be 
investigated which we did not have available to us, however, it does present an interesting 
area of research for future studies. 
It is also possible the model used here could have hindered or slowed matrix 
remodelling of more dense matrices as T-lymphocytes are known to degrade GAGs in vivo 
and were absent from our model (35). Had these T-lymphocytes been present faster bone 
formation from samples which had a more GAG rich matrix may have been observed, 
however this would require an immunocompetent model in order to verify. We have used 
immunocompromised mice, lacking functioning T and B cells, a model which is often 
employed in ectopic bone formation studies (36, 37). Our group has previously shown 
that it is possible to take chondrogenically primed MSCs from rats and implant them into 
immunocompetent animals to achieve bone formation (20). It has not been studied yet 
whether human MSCs would make bone in an immunocompetent animal. As we implant 
human MSC pellets in a mouse environment we utilised an immunodeficient mouse 
model to avoid xenographic rejection. This study was a proof of principle study in order 
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to characterise and determine the de novo bone forming potential of the µpellet-fibrin 
constructs we implanted our constructs in a subcutaneous environment which we felt 
was the best environment to determine this. We chose to do this instead of a large bone 
defect as we were able to better adhere to the 3R principle (38); safely implanting more 
conditions per animal allowing for fewer animals with minimal discomfort to be used to 
complete our study. Subcutaneous implantation of our relatively small constructs did not 
hinder their movement or range of motion. Constructs were not in an environment where 
bone forms naturally and this may have limited the bone formation and remodelling we 
observed within our constructs. Future studies which investigate these constructs in a 
defect environment will be useful. 
µpellet-fibrin constructs were found to have equivalent calcification volumes (as 
assessed by µCT) after in vivo implantation when compared to pellets cultured for the 
same time. These volumes even after 28 days of culture pre-implanation are still far 
from sufficient to properly heal a large bone defect. As we have not studied how these 
constructs perform in a large defect we cannot say how they would calcify and integrate 
with the host bone tissue. Furthermore the inherent donor differences we observed meant 
that although samples were primed for the same time, the ultimate bone formation varied 
after implantation.  This donor variation is an area of active research and by furthering our 
understanding of what is crucial for endochondral bone formation to take place in vivo in 
response to certain in vitro produced ques is essential for this research to move forward. 
In addition there is often a lack of bridging between standard pellets which needs to be 
addressed for proper integration of such constructs with host tissue. Scale-up approaches 
are still an area of active research in this field and in the future we hope to investigate 
these µpellets using bioactive injectable matrices in large bone defects to increase bone 
formation. Additionally, understanding the relationship between matrix composition 
pre-implantation and the subsequent effect on bone formation in vivo is important and 
merits further investigation, as determining an optimal set of criteria for chondrogenesis 
pre-implantation to achieve bone formation in vivo will improve future research. This 
is also important because identifying such criteria would result in more reproducible 
outcomes which is crucial for the translation of such constructs to the clinic. Still we find 
the bone forming potential of these novel µpellet constructs to be promising. We believe 
with further optimisation of in vitro culture we could optimise these constructs as an 
injectable bone construct which would be advantageous to treat bone defects. 
CONCLUSIONS 
This study has shown it is possible to greatly decrease in vitro culturing for pellet and 
µpellet constructs and still retrieve bone after implantation. With further optimisation 
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of culture conditions and material parameters µpellets could be offer a promising 
alternative to current clinical treatment options for bone defects. We also believe µpellets, 
due to their small size, could be easily optimised as an injectable therapy using either 
a thermoreversable gel or injectable fibrin-based material allowing for the creation of a 
customisable void filling bone substitute. Given the shorter priming time required coupled 
with injectability, this approach could offer promise for a minimally invasive therapy to 
replace some autologous bone transplantation procedures. 
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Abstract
Treatment of large bone defects due to trauma, tumor resection, or congenital 
abnormalities is challenging. Bone tissue engineering using mesenchymal stem cells 
(MSCs) represents a promising treatment option. However, the quantity and quality of 
engineered bone tissue are not sufficient to fill large bone defects. The aim of this study 
was to determine if the addition of enamel matrix derivative (EMD) improves in vitro 
chondrogenic priming of MSCs to ultimately improve in vivo MSC mediated endochondral 
bone formation. MSCs were chondrogenically differentiated in medium supplemented 
with TGFβ3 in the absence or presence of 1, 10, or 100 µg/mL EMD. Samples were analyzed 
for gene expression, glycoaminoglycan (GAG) production, and histologically. Osteogenic 
and adipogenic differentiation capacity were also assessed. The addition of EMD did not 
negatively effect chondrogenic differentiation of adult human MSCs. EMD did not appear 
to alter GAG production or expression of chondrogenic genes. Osteogenic and adipogenic 
differentiation were likewise unaffected though a trend toward decreased adipogenic 
gene expression was observed. EMD does not effect chondrogenic differentiation of adult 
human MSCs. As such the use of EMD in combination with chondrogenically primed MSCs 
for periodontal bone tissue repair is unlikely to have negative effects on MSC differentiation.
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INTRODUCTION
Trauma, tumor resection or congenital abnormalities can result in large bone defects. 
Treatment options for such defects include the use of autologous bone grafts, allogenic 
bone or other substitute material (1, 2). Autologous bone is preferred clinically; however, 
harvesting of material can result in secondary site morbidity and an increased risk of 
infection (1). In addition, tissue availability is limited, increasing the demand for an 
alternative graft substitute (3). 
Tissue engineering represents a promising alternative treatment option for bone 
defects. Mesenchymal stem cells (MSCs), available from sources including bone marrow 
and adipose tissue, are multipotent cells that can be differentiated towards the osteogenic 
and chondrogenic lineages (10) making them an attractive cell source for bone tissue 
engineered constructs. 
Multiple approaches have been taken to improve osteogenic differentiation of 
MSCs, mimicking the process of intramembranous ossification, including manipulating 
growth factors, scaffolds, and environmental parameters (e.g., oxygen and pressure) (5). 
Unfortunately, due to insufficient vascularisation of the MSC based implant necrosis, 
improper nutrient delivery, and inadequate waste removal occur, ultimately resulting in 
graft failure. 
Bone tissue constructs modeled after the process of endochondral ossification (EO) 
may result in more promising outcomes as the initial tissue (cartilage) would be better 
suited to survive the initial avascular implantation site. During EO, cartilage is formed by 
chondrogenic differentiation of MSCs in vitro. Since chondrocytes reside in an avascular 
environment, they can survive the initial hypoxic insult following implantation (6). As the 
chondrocytes mature, become hypertrophic and apoptose, blood vessels invade and 
the cartilage rich matrix is mineralised ultimately serves as a template for future bone 
development. Several groups have produced promising results using MSCs guided bone 
formation along the process of EO in vivo (7-13). Van der stok et al. demonstrated the 
ability of such constructs to repair a long bone defect in recent proof of principle studies 
(13).  Despite the promise of this approach, the resulting bone is often not sufficient to 
fill large clinically relevant defects, indicating a need to improve current techniques to 
optimize bone formation. Many researchers have investigated combining MSC with 
clinically relevant compounds to improve in vivo bone formation.
Enamel matrix derivative (EMD) is an extracellular matrix derivative obtained from 
porcine tooth buds. It contains amelogenin and proteins that belong to the amelogenin 
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family (>90%) (14).  Sold commercially as Emdogain, EMD in a single dose syringe dissolved 
in propylene glycol alginate. Emdogain is used clinically to stimulate the regeneration of 
periodontal tissues. Combining EMD with surgical periodontal therapy (surgical therapy 
of the tissue surrounding or encasing teeth) of deep intrabony defects lead to improved 
clinical parameters compared to surgical therapy alone (2). Studies have shown that EMD 
stimulates the proliferation and osteogenic differentiation of MSCs (14-17). However, 
many groups used only specific proteins that are included in EMD or based their results 
on cells obtained from animals or cell-lines. Narukawa et al. found a stimulatory effect 
of Emdogain on the expression of chondrogenesis related transcription factors in 
chondrogenically primed MSCs. Utilizing a chondrogenic cell line, the group observed 
an increase in glycosaminoglycans (GAGs) quantity in the extracellular matrix (15, 18). 
EMD was also shown to increase the proliferation of early chondrocytes derived from 
rats and inhibited maturation. In mature chondrocytes, EMD enhanced proliferation and 
did not inhibited differentiation (19). Due to its clinical relevance and previous evidence 
suggesting an effect of EMD on chondrogenesis EMD was hypothesized to improve in 
vitro chondrogenic priming of human MSCs. These chondrogenically primed human 
MSCs could be utilised as a tissue engineered MSC based endochondral bone graft. The 
aim of this research was to determine if EMD enhanced chondrogenesis in human MSCs 
and to determine if EMD improves the quantity and quality of the chondrogenic matrix 
production. In order to compare with previous research, we also assessed the osteogenic 
capacity of MSCs in the presence of varying doses of MSCs as well as their adipogenic 
differentiation capability.
MATERIALS AND METHODS
EMD Enamel matrix derivative was supplied as a freeze dried preparation by Straumann 
Company. It was reconstituted in 50 mM acetic acid to 10 mg/mL and further diluted to 
the working concentrations below in the appropriate culture medium. 
Mesenchymal stem cell isolation
MSCs were isolated from three human bone marrow samples aspirated from the greater 
trochanter major from patients undergoing total hip arthroplasty, after informed consent 
(METC 2004-142) from two females (aged 20 and 60) and one male (aged 54). MSCs showed 
similar growth and differentiation characteristics. MSCs were maintained in expansion 
medium (α-mem (Gibco) containing 10% FCS (Lonza), supplemented with 1 ng/mL FGF2, 
25 µg/mL ascorbic acid) at 37°C and 5% CO₂ as described previously (20). 
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Adipogenic differentiation
MSCs were cultured in 12-well plates at a density of 2.1x104 cells/cm2. Cells were cultured for 
14 days at 37°C and 5% CO₂ in adipogenic induction medium (DMEM containing 10% FCS, 
supplemented with 1 µM dexamethasone, 0.2 mM indo-methacin, 0.01 mg/mL insulin, 0.5 
mM 3-isobutyl-l-methyl-xanthine (Sigma)). EMD treated samples were cultured in 1, 10, or 
100 µg/mL EMD or vehicle alone (0.5 mM acetic acid). Medium was replaced twice a week.
Osteogenic differentiation
MSCs were cultured in 12-well plates at a density of 3x103 cells/cm2. Cells were cultured 
for 15–19 days at 37°C and 5% CO₂ in osteogenic induction medium (high-glucose DMEM 
(Invitrogen) with addition of 10% FCS, 50 µg/mL gentamycin (Invitrogen), 1.5 µg/mL fungizone 
(Invitrogen), 10 mM glycerol 2-phosphate (Sigma), 0.1 µM dexamethasone (Sigma), 0.1 mM 
ascorbic acid (Sigma)). EMD treated samples were cultured in 1, 10, or 100 µg/mL EMD or 
vehicle. Medium was replaced twice a week. Samples were harvested at the latest point, 
prior to detachment of the cells from the surface of the tissue culture plastic, as occurs during 
osteogenic differentiation in monolayer. This varied from 15–19 days between donors. 
Chondrogenic differentiation 
MSCs were cultured for 21 or 35 days in pellets of 2.0 × 105 cells in 500 µl chondrogenic 
medium (high-glucose DMEM supplemented with 50 µg/mL gentamycin (Invitrogen), 
1.5 µg/mL fungizone (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 40 µg/mL proline 
(Sigma), 1:100v/v insulin-transferrinselenium (ITS; BD Biosciences), 10 ng/mL transforming 
growth factor β1 (R&D Systems), 25 µg/mL ascorbic acid (Sigma), 100 nM dexamethasone 
(Sigma)). EMD treated samples were cultured in 1, 10, or 100 µg/mL EMD or vehicle alone. 
Medium was replaced twice a week. 
Oil red O staining
Lipid droplets were stained by Oil Red O. Cells in monolayer were washed in 0.9% NaCl 
and fixed for 1 h in 4% paraformaldehyde. Cells were stained with Oil Red O (0.3% w/v in 
distilled water; Sigma) for 10–15 min and washed with distilled water. Cells were mounted 
with Vectamount.
von Kossa staining 
Monolayers were washed in 0.9% NaCl, fixed with 4% formaldehyde for 1 h and stained with 
von Kossa staining. Cells were incubated in 5% silver nitrate and placed on a light box for 
15 min. Excess silver nitrate was washed using distilled water and cells were placed on a 
light box for another 10 min. Cells were washed in distilled water and counterstained with 
thionine for 5 min. Cells were dehydrated in 70% (10 s), 96% (30 s), and 100% ethanol (2 
min) and mounted with Vectamount.
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Scaffold seeding
Collagen-GAG scaffolds were cut in 8 mm squares, placed in 6-well plates coated with 2% 
agarose (LE- analytical grade, Promega). Scaffolds were seeded with 5 × 105 cells in 150 
µL culture medium on one side, incubated for 30 min then overturned and seeded again 
with the same cell number and volume. After another 30 min, the well was filled with 3 mL 
of culture medium. Constructs were cultured in chondrogenic medium with the addition 
or absence of 10 ng/mL transforming growth factor-β 1 (TGF-β1) and/or 100 µg/mL EMD. 
Samples were cultured at 37°C and 5% CO₂.
Gene expression analysis
RNA was isolated from chondrogenic pellets by homogenising samples with a 
Eppendorf-potter in 350 µL RNAbee (Freund Can Company). Adipogenic and osteogenic 
primed MSCs cultured in monolayers were harvested as follows: 2-wells were combined 
in 300 µL RNAbee, samples and stored at -80°C. RNA isolation, cDNA synthesis, 
and measurement of gene expression levels on 8–15 ng cDNA were performed as 
described before (200, 201). Primers and probes used for alkaline phosphatase (ALPL), 
Gamma-carboxyglutamic acid-containing protein (BGLAP), Integrin-binding sialoprotein 
(IBSP), Collagen type I (COLI), Peroxisome proliferator-activated receptor γ (PPARγ), Fatty 
acid-binding protein 4 (FABP4), Runt-related transcription factor 2 (RUNX2), Collagen 
type II (COL II), Collagen type X (COL X), Sex determining region Y-box 9 (SOX 9), and 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Biochemical assay
Pellets and scaffolds were digested in 150 µL papaine digestion solution in combination 
with 150 µL sodium citrate buffer. GAGs were measured and adjusted to the amount 
of DNA present in each pellet or scaffold as described before using heparin (Leo 
Pharmaceutical Products BV), RNAse (Ribonuclease type III-A; Sigma), and ethidium 
bromide (GibcoBR1) (22).
Histology sample preparation
Pellets and scaffolds were fixed in 4% paraformaldehyde for 1 h, embedded in liquid 
paraffin wax, and cut into 5 µm sections using a microtome (Leica RM2135). Sections 
were placed onto SuperStar® microscope slides and de-waxed by soaking sequentially in 
xylene and 100, 96, and 70% ethanol (5 min each).
Histology
GAG formation was determined by 0.1% safranin O staining and cell morphology 
was determined utilizing H&E staining. Stainings were performed as described 
previously (23, 24).
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Immunohistology 
Antigen retrieval was performed using 0.1% pronase and 1% hyaluronidase. Sections were 
incubated with 1:100 mouse monoclonal antibody against collagen type II and stained by 
an ALPL substrate as described before (23).
Statistics
Data are presented as mean values±SD. Statistical analysis was carried out using repeated 
measures ANOVA test followed by Tukey post hoc correction using a statistical software 
package (Prism 5.00, Graphpad Software). Results were considered statistically significant 
at p < 0.05. 
RESULTS 
EMD does not effect the osteogenic differentiation capacity of human MSCs
Osteogenic genes ALPL, BGLAP, IBSP, and COL I were analyzed after 15–19 days by real-time 
PCR. No differences were observed between osteogenic control, vehicle, and the different 
doses of EMD (p-values respectively 0.1600, 0.2578, 0.6016, and 0.5673; figure 1). 
Figure 1: Measurement of gene expression levels for osteogenic genes. 
Gene expression was measured in MSCs cultured in osteogenic medium 
for 15–19 days. Data represent fold changes of target genes relative to 
the housekeeping gene GAPDH. Values represent the mean ± SD for 
samples from three donors.
Despite inter-donor variability, no differences were observed in the amount of calcium 
phosphate-nodules formed at the macroscopic level (figure 2). This suggests that EMD had 
no effect on the osteogenic differentiation of MSCs.
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Figure 2: Evidence of osteogenic differentiation of MSCs exposed to osteogenic factors for 19 days. Images 
represent von Kossa staining for MSCs of one donor cultured in the non-differentiation medium α-MEM as a negative 
control (A) MSCs cultured in osteogenic differentiation only (B), MSCs cultured in osteogenic differentiation medium 
in presence of the vehicle (C), and MSCs cultured in osteogenic differentiation medium in presence of 1, 10, or 100 
µg/mL EMD (D–F)Arrows indicate calcium phosphate-containing nodules.
EMD has no effect on the adipogenic differentiation of human MSCs 
Adipogenic genes, FABP4 and PPARγ, were investigated for three donors by real-time 
PCR after 14 days to determine the role of EMD on adipogenesis. Cells cultured in 
the high dose EMD (100 µg/mL) showed a trend toward inhibition of gene expression 
compared to vehicle and adipogenic control. However, given the large inter-donor 
variability, this difference was not statistically significant for FABP4 (p = 0.4835) or PPARγ 
(p = 0.1063; figure 3). 
Figure 3: Measurement of gene expression levels for PPARγ and FABP4. Gene expression was measured in MSCs 
cultured in adipogenic differentiation medium for 14 days with addition of vehicle or different doses of EMD (1, 
10, or 100 µg/mL). Data represent fold changes of target genes relative to the housekeeping gene GAPDH. Values 
represent the mean ± SD for samples from three donors.
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The effects of vehicle and EMD on adipogenic differentiation were also assessed by 
Oil Red O staining of fat-containing droplets. No cells cultured in the expansion medium 
(used as a negative control) showed evidence of fat-containing droplets (figure 4A). 
When MSCs were cultured in all other treatment conditions, cells positively stained in 
all conditions (Figures 4B–F). Staining was slightly reduced in the high dose EMD (100 
µg/mL) compared to adipogenic control or vehicle across all donors and wells. This 
suggests, together with the results for FABP4 and PPARγ, a potentially inhibitory effect of 
EMD on adipogenic differentiation of MSCs at the highest dose. However, this effect was 
minimal as determined by staining.
Figure 4: Oil Red O staining illustrates adipogenic differentiation of MSCs exposed to adipogenic factors for 14 
days. Images represent MSCs cultured in the non-differentiation medium α-MEM (A), MSCs cultures in adipogenic 
differentiation medium only (B), MSCs cultured in adipogenic differentiation medium in addition of vehicle only 
(0.5 mM acetic acid) (C), and MSCs cultured in adipogenic differentiation medium in addition of 1, 10, or 100 µg/
mL EMD (D–F).
EMD does not effect the chondrogenic differentiation capacity of human MSCs 
Chondrogenically primed cell pellets were analyzed by real-time PCR after 21 days for 
three donors. Four different chondrogenic genes were analyzed; COL II, COL X, SOX 9, 
and RUNX2 (figure 5). After treatment with vehicle only or EMD, no statistical significant 
differences in COL II (p = 0.0538), COL X (p = 0.2457), SOX 9 (p = 0.7458), or RUNX2 (p 
= 0.5863) mRNA levels were observed between groups. GAG-production measured in 
control was approximately 40 µg GAG per microgram DNA. There was no effect of EMD at 
any concentration on the quantity of GAG production (p = 0.8989; figure 5B). 
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Figure 5: Gene expression levels of chondrogenic genes following differentiation. (A) Gene expression was 
measured in MSCs cultured in chondrogenic differentiation medium treated with vehicle only or different doses of 
EMD (1, 10, or 100 µg/mL) for 35 days. Data represent fold changes of target genes relative to the housekeeping gene 
GAPDH. Values represent the mean ± SD for samples from three donors. (B) Quantification of GAGs in MSCs cultured 
with chondrogenic factors. Data represent amount of GAGs normalized to DNA content in each pellet
Figure 6: Histological analysis of chondrogenic differentiation of MSCs exposed to chondrogenic factors for 
35 days. Images represent MSCs cultured in chondrogenic differentiation medium only (A, F), MSCs cultured 
in chondrogenic differentiation medium in addition of vehicle only (B, G), and MSCs cultured in chondrogenic 
differentiation medium in addition of 1 µg/mL (C, H), 10 µg/mL (D, I), or 100 µg/mL EMD (E, J). GAGs were stained by 
Safranin O (A–E), COL II immunohistochemistry was performed for images (F–J).
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Following 35 days of culture in chondrogenic medium, or in the presence of 
vehicle, or EMD, chondrogenic pellets were stained with safranin O (Figures 6A–E). 
Immunohistochemical staining for COL II was also performed on these pellets (Figures 
6F–J). All pellets demonstrated high quantities of GAGs stained by safranin O and 
collagen type II. However, no differences in staining were observed between pellets in 
the chondrogenic control conditions or in the presence of different doses of EMD (1, 10, 
or 100 µg/mL).
MSCs in 3D culture 
In order to assess the effects of EMD on the cell distribution and chondrogenic 
differentiation in a 3D environment, two collagen-GAG scaffolds were seeded with 
human MSCs and cultured in the presence or absence of TGFβ1 (10 ng/mL) and/or EMD 
(100 µg/mL). Hematoxylin and eosin staining demonstrated similar cellular distribution 
in both conditions (Figures 7A–D). Thionine staining illustrated the presence of GAGs in 
both conditions (Figures 7E–H). 
Upon quantification of the amount of GAG production in two scaffolds per condition, 
less GAG/DNA was produced in the TGFβ1 + EMD condition (figure 8). As this was only 
performed with cells from one donor, it was not possible to statistically analyze these 
results.
Figure 7: (A–D) Distribution of MSCs through the collagen-GAG scaffolds cultured under the four different conditions 
(H&E staining). (E–H) Staining for GAGs produced by MSCs seeded on collagen-GAG scaffolds cultured whether or 
not in presence of TGF-β and/or EMD (thionine staining).
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.  
Figure 8: Quantification of GAGs in MSCs seeded on scaffolds 
cultured with chondrogenic factors for 21 days (two samples 
from one donor for each condition).
DISCUSSION
 
Current treatment options for the treatment of large bone defects, such as autologous 
bone or bone substitutes, are often accompanied by limitations and serious complications, 
highlighting the necessity for an alternative treatment option (1, 3, 25, 26). Reports of EMD on 
MSC osteogenesis are mixed (10, 14, 16, 18, 27) while little is known about the effects of EMD 
on chondrogenesis of human MSCs. Tissue engineered bone formation modeled after EO, 
in which MSCs are chondrogenically differentiated in vitro and then implanted, represents a 
promising avenue for bone tissue engineering (10). We hypothesised that, given the reported 
abilities of EMD to improve cell proliferation, migration, and differentiation (particularly 
during osteogeneic differentiation) (15-17, 27), EMD might also improve the chondrogenic 
priming of human MSCs. In this study, we focused on chondrogenic differentiation of adult 
human MSCs as a first step to tissue engineering bone via the process of EO. In order to 
put the work in the context of prior research, we also assessed osteogenic and adipogenic 
differentiation of these cells in the presence of EMD. 
No differences were observed in GAG production nor in COL II expression in any of 
the conditions. While the group of Narukawa found an upregulation of COL II, COL X, and 
SOX 9, as well as increased GAG production following chondrogenic treatment of the 
ATDC5 hypertrophic cell line in the presence of Emdogain (15), we observed no effects 
on chrondrogenic differentiation in primary human MSCs. Given the natural tendency of 
ATDC5 cells to progress along  the chondrogenic lineage toward hypertrophy, it is hard to 
directly compare the two cell types. The effect of EMD on cell migration and chondrogenesis 
in a 3D environment, a collagen-GAG scaffold, was also analysed in this study. This was 
performed using cells from a single donor on two scaffolds per condition. On histology, 
no differences were observed between chondrogenically treated groups. However, while 
chondrogenisis did occur, there was a trend toward decreased GAG production in the EMD 
treated samples. This experiment would require repetition with MSCs from several donors 
to confirm if this is the case. 
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We observed no effect of EMD on extracellular matrix production or on gene level 
when stimulated osteogenically. This is in agreement with the work of some other groups 
(28, 29). However, other groups also stated EMD, or components of it, stimulated the 
differentiation of MSCs toward osteocytes (15, 30-32). These utilised both cell lines and 
rat derived MSCs, as well as only selective proteins found in EMD, which may explain the 
differences observed. Considering published work and our results, we have no evidence 
to support the idea that EMD would negatively influence osteogenic differentiation of 
human MSCs. The in vivo effects of EMD on ossification remain unclear. Some groups 
reported enhanced bone induction in vivo in animal models and humans (33-35) while 
others showed no effect of EMD on the formation of mineralized bone (36). Yagi et al. 
showed that EMD inhibits RANKL expression, resulting in inhibited osteoclast formation, 
the cells that are responsible for bone resorption (37). The variability in these results 
could be caused by numerous factors including variable biological characteristics due 
to of the defect and patient variability (38). However, these results are based on bone 
formation by surrounding cells instead of implanted chondrogenically primed cells. It is 
difficult to extrapolate the results observed in this study to an in vivo/clinical situation. 
We observed a mild trend toward inhibition of adipogenic differentiation at the highest 
dose of EMD on human MSCs. No tests have been performed to determine the effects 
of EMD on adipogenic differentiation of MSCs previously. The decreasing trend toward 
adipogenic differentiation of MSCs, in this proposed application, could be considered 
a positive outcome suggesting undesirable fat tissue formation is unlikely, or could be 
that in adipogeneic differentiation EMD at high doses is mildly toxic.
Enamel matrix derivative does not appear to effect the multilineage differentiation 
of human MSCs. There may be a slight inhibitory effect of EMD, at the highest dose, 
on adipogenesis. However, this was not proven to be statistically significant. While 
this work suggests that EMD would not increase the chondrogenic potential of MSCs, 
which could be utilised in a bone tissue construct via EO for the treatment of large 
bone defects, there is also no evidence that tissue formation/bone formation would 
be inhibited if EMD was used in combination with MSCs for the repair of minor bone 
defects or periodontal tissue repair.
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OVERVIEW
Large bone defects are challenging to treat clinically, often relying on the use of autologous 
bone grafts (ABGs), which are in limited supply (1-3). As early as the 18th century surgeons 
had already begun investigating different alternative bone substitutes (3); some of the 
methodologies tested then, such as the use of decalcified bone (4), still persist today. 
However, understanding of defect repair and regeneration has since improved, resulting 
in better approaches to tissue engineered (TE) bone formation. 
Cell based approaches to bone repair are often utilised in tissue engineering, usually 
modelled after one of the developmental pathways of bone formation, with mesenchymal 
stem cells (MSC) typically the preferred cell source due to their chondrogenic and 
osteogenic differentiation potential (5, 6). As mentioned in this thesis, MSC constructs 
modeled after intramembranous ossification are often unfavorable due to poor survival 
and integration rates (7) and as such the research in this thesis exploited the endochondral 
ossification (EO) pathway. The cartilage intermediate often employed in TE EO is thought 
to be well suited to survive in the initial avascular, hypoxic environment (8), and through 
the secretion of bioactive molecules and a biologically relevant extracellular matrix (ECM) 
these constructs can recruit cells from the host important for vascularization (9, 10), matrix 
remodeling (11-14) and ultimately bone formation (12, 15). 
The aim of this thesis was to improve TE EO constructs and our understanding of how they 
work as well as to investigate how current constructs could be improved to meet clinical 
needs. Specifically, by identifying a superior cell source compared to the gold standard 
adult MSCs (A-MSCs) we present a more reliable and culture sustainable cell source, ideal 
for tissue engineering (chapter 3). We then investigated the role of collagen type X (COLX) 
produced by MSCs which appeared essential to the process but had never previously been 
investigated in a TE setting. In this chapter we prove the importance of this collagen not 
only during in vitro cartilage formation but also subsequent bone formation (chapter 4). 
After identifying a more reproducible cell source and discovering the importance 
of COLX in TE EO, we started to investigate ways we could improve chondrogenic 
MSC constructs to meet clinical needs and expectations. First we created a clinically 
relevant micropellet system for use, ultimately, as an injectable bone substitute to 
allow for a minimally invasive, easily applicable TE bone treatment option for clinicians 
(chapter 5) (16). However, as is often the case, bone defects occur concurrently with soft 
tissue damage which also requires surgical intervention to heal properly. By investigating 
the combination of MSCs with a commercially available product, enamel matrix derivative 
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(EMD), used in the regeneration of soft tissue surrounding the bone defect site, 
(chapter 6) we showed with further development there may be potential to combine 
the injectable micropellet constructs (chapter 5) with EMD to allow for the treatment 
of both bone and soft tissue damage concurrently. Together, these studies improve the 
construction and understanding of TE EO, and also highlight new clinical application 
possibilities for the future. Below, we discuss the new findings presented in this thesis 
as well as focus on future applications and perspectives for EO grafts.  
IMPROVED CELL SOURCES FOR TISSUE ENGINEERED ENDOCHONDRAL 
OSSIFICATION
MSCs are an attractive cell source for TE and regenerative medicine, however their 
unpredictable behaviour and tissue culture induced changes limit their applications (17, 
18). Adult bone marrow derived MSCs (A-MSCs) have been the golden standard cell source 
for many years despite their unpredictable nature. Paediatric MSCs (P-MSCs), however, can 
be easily isolated from surplus iliac crest bone chips by an easily reproduced protocol. As 
opposed to A-MSCs these P-MSCs showed better expansive properties, yielding more MSCs 
with less senescence per passage than adult counterparts. The compromised regenerative 
capacity of aged cells may be due to the accumulation of senescent cells (18, 19); so, from 
a tissue engineering perspective, it may be advantageous to have a lower percentage of 
senescent cells in the overall population. Lehmann et al. have shown senescent MSCs 
within the starting population can induce senescence in the non-senescent cells present 
in culture as expansion continues (in preparation; abstract presented during International 
Cartilage Regeneration and Joint Prevention Society in 2018). This will lead to poor cell 
expansion rates as the cells continue to be passaged. For experiments requiring large cell 
numbers, or those which require extensive passaging of MSCs as is the case with lentivirus 
work (chapter 4) our P-MSCs are an attractive cell source.  
Here we show even after more extensive passaging (passage 5 in chapter 3; passage 
7 in chapter 4) P-MSCs exhibit/maintain their chondrogenic differentiation capacity, and 
we show they are capable of more consistent trilineage differentiation (chapter 3) which 
outperformed the capacity of A-MSCs at earlier passages. As pointed out by Arnold Caplan, 
the developmental demands on the body of a newborn versus that of a 70 year old are 
different, and these differences more than likely directly contribute to the age related 
changes we see in MSCs (20). As our P-MSCs are obtained from younger patients, who are 
still thought to be actively developing endochondral bone into their late 20s to early 30s 
(21)(22), it may reason that they would be better at regenerating these tissues than cells 
from patients well beyond this developmental stage. Additionally, as many adult MSCs 
are affected by age-related cell dysregulations (20), our MSCs from a paediatric source 
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are likely not to be affected by these problems, which could have contributed to their 
enhanced culture characteristics. Although their superior proliferation and differentiation 
capacity is clear, it must be pointed out that P-MSCs are still susceptible to a certain degree 
of donor-variation (chapter 3, figure 6), which will result in varying in vivo results (chapter 
4 & 5). Identifying which subset of MSCs is responsible for chondrogenic differentiation 
may reduce this variability, and remains the focus of many research groups (23). Moreover, 
isolating such subsets from even younger cell sources, such as foetal or embryonic, could 
provide significant improvements compared to P-MSCs, although this can be difficult as 
these materials are in limited supply. As P-MSCs can be easily isolated from a source that 
would otherwise be deemed clinical waste we have found a way to not only reduce waste 
but utilise it in a meaningful way. By identifying this cell source we have provided those in 
the regenerative medicine community with a more reproducible and reliable cell source 
compared to the current gold standard. 
INVESTIGATING MSC MEDIATED ENDOCHONDRAL OSSIFICATION 
Identifying an ideal MSC cell source or chondrogenic cell subset is just the beginning. 
Our understanding of in vitro chondrogenic differentiation for reproducible in vivo bone 
formation must be improved; discovering what is essential for successful cartilaginous 
differentiation and subsequent in vivo bone formation will significantly improve what can 
be achieved in the field. Collagen type X (COLX) is an EO-associated collagen present both 
during in vitro chondrogenic induction (24) and in vivo bone formation (25) whose role in 
developmental EO is often debated (26, 27) but has never been studied in context of TE 
EO.  COLX has been hypothesised to be vital for proper construction of the pericellular 
network (28, 29), adding structural support which is crucial during matrix remodeling 
(28), and is thought to play a role in initiating biomineralisation during bone formation by 
allowing selective binding of matrix vesicles (30-32). We show that COLX is expressed early 
and consistently during in vitro chondrogenic differentiation of MSCs (chapter 5) (24), 
suggesting it is important for successful chondrogenic differentiation. 
Knocking-down COLX (chapter 4) altered chondrogenic induction of MSCs resulting in 
reduced levels of key ECM components and secreted factors. Interestingly in addition to 
the altered matrix formation, several secreted factors were found to be downregulated 
when COLX expression was decreased. FGF and PDGF, factors usually present during 
fracture repair, were among these factors. PDGF is important for EO as it plays a role 
in osteoblastic differentiation (33) and vessel stabilisation (34). FGF likewise plays an 
important role in EO, as it is essential for chondrocyte proliferation (16, 35). TNFα was 
also downregulated following COLX inhibition. This is of particular interest as TNFα is also 
found to play in osteoclastic recruitment and bone turnover (36, 37). Without COLX, not 
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only was the matrix greatly affected but the secreted profile, which also contributes 
to important cell recruitment and behaviour in vivo, are greatly impaired. MSCs with 
decreased COLX expression have decreased in vivo bone forming potential, further 
supporting the importance of COLX in MSC mediated EO.  However, we also see in this 
experiment that there appears to be a certain threshold of COLX expression which is 
sufficient for chondrogenic differentiation and bone formation to occur. Determining this 
threshold is important for future studies as it can be used as a way to screen implants 
pre-implantation to determine the likelihood of bone formation in vivo. Additionally 
determining if greater COLX expression over this threshold has a positive effect on bone 
formation would likewise be interesting, perhaps an overexpression of COLX would 
improve bone formation. 
The use of other knock-down methods, such as the CRISPR/cas system which is 
capable of targeted gene editing, would provide further support to our finding. This 
system, however, would require clonal expansion, a technique quite challenging to 
achieve with primary MSCs. Instead, an immortalised MSC cell line, such as TERT-MSCs 
(38), could be used with this technique. The use of a cell line would also help overcome 
the donor variability observed when using primary MSCs. 
It would be interesting to see if the overexpression of COLX would improve in vivo bone 
formation as the knock-down has such negative effects. The exact timing of the over 
expression would need to be investigated however as inducing an over expression from 
the start may not be favourable as COLX is a hypertrophic associated collagen and early 
expression may hinder proper chondrogenic differentiation thus negatively affecting how 
the MSCs differentiate or produce the ECM. Regardless it is clear COLX plays an important 
role not only in chondrogenesis but also during bone formation by chondrogenic MSCs. 
MODIFYING THE CURRENT MSC PELLET CULTURE SYSTEM FOR INJECTABILITY
 
Cell based TE EO is often achieved via in vitro chondrogenic differentiated MSCs in the 
form of pellets (chapter 1, figure 3). The resulting chondrogenic pellets (generally 200,000 
cells/pellet) have been shown to form bone in vivo after 21-28 days of chondrogenic 
differentiation (39-41). However, when an irregular defect exists the current pellet system 
may not allow for sufficient treatment of the defect as they cannot sufficiently fill the 
defect site. This issue was addressed by creating a novel micropellet culture system 
(10,000 cells/pellet) which was shown to be capable of bone formation following only a 
week of chondrogenic differentiation. These micropellet constructs, which are capable 
of recruiting cells important for matrix remodelling, vessel invasion and bone formation 
(chapter 5), would allow for tailored void filling of irregular defects once optimised as an 
injectable bone substitute (24). 
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Before investigating the bone forming potential of micropellet constructs we needed 
to prove that the scaled down pellet constructs would maintain the chondrogenic 
potential observed in standard pellets. Chondrogenic priming time could be achieved in 
just one week, indicating the time required for in vitro culture before implantation could 
be substantially shortened, making future constructs available faster than previously 
thought. However bone formation was only reproducible when constructs were 
encapsulated in fibrin. Fibrin can create a hypoxic environment (42) which is favourable 
for both osteoclastic (43) and osteoblastic (44) activity, which may explain why when 
encapsulated in fibrin bone formation was possible. In our micropellet constructs fibrin 
allowed for a more three dimensional distribution of pellets within the fibrin. This could 
mean micropellets must be in closer proximity to one another to allow for better cross-talk 
between them. It could be thought the fibrin itself is the essential element, however, we 
also found when encapsulated in alginate chondrogenesis was also achievable which may 
indicate that oxygen tension is a more critical factor (unpublished). Further investigation 
into improving culture methodology, perhaps via a bioreactor, to ensure in the absence 
of fibrin chondrogenic differentiation can be achieved would be advantageous. Another 
avenue could be to use a thermo-reversible biomaterial which would allow the micropellets 
to stay in close proximity and still allow for injectability following differentiation. From a 
clinical standpoint however fibrin is advantageous as it is already a FDA approved material 
(45).
Optimising micropellets as an injectable substitute would be beneficial as it would 
be easily applied and offer a minimally invasive treatment option for clinicians. In the 
future, using micropellets in combination with functionalised injectable fibrin gels with 
proteins which are known to aid in the recruitment of cells required during EO or those 
known to improve bone formation such as BMP2 (discussed further in chapter 2) could 
result in greater bone formation which would allow for improved treatment. Additionally 
these micropellets could be used in combination with compounds such as Enamel matrix 
derivative (EMD) (chapter 6) to create an injectable treatment for both bone and soft tissue 
defects.
SOFT TISSUE REGENERATIVE COMPOUNDS ON MSC BEHAVIOUR, TOWARDS 
COMBINATIONAL THERAPEUTIC APPROACHES
Often when bone injuries occur, the surrounding soft tissue will be affected. Our constructs 
as presented here only form bone meaning other factor(s)/compound(s) would be 
required to regenerate the damaged soft tissues. EMD is a commercially available product 
for ligament repair that has previously been shown to improve stem cell proliferation and 
osteogenic differentiation (46-48). However if we were to use EMD in combination with 
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chondrogenic pellets, perhaps suspended around our pellet/micropellet constructs, we 
needed to determine if the addition of EMD to our system would have deleterious effects 
which would prevent its use in combinational therapy approaches. 
We demonstrated that the trilineage differentiation potential of MSCs was not hindered 
by EMD (chapter 6). This is interesting as the addition of EMD to our system may not 
affect the trilineage differentiation potential of endogenous stem cells which are crucial 
for bone formation in our system. This suggests EMD would be a promising candidate for 
combinatorial therapy approaches using chondrogenically differentiated MSCs. However, 
further studies into the in vivo performance of the two together are necessary to ensure 
EMD does not hinder the bone forming potential of the chondrogenically differentiated 
MSCs and ensure there are truly no negative influences the endogeneous MSCs in vivo. 
This combinational therapy could be tested in an osteochondral defect model (49) in 
order to gauge the regenerative capacity of the construct in an area where both tissue 
types could be regenerated. As EMD is suspended in propylene glycol alginate (PGA) 
supplied as an injectable compound, it would be ideal to use in combination with an 
injectable chondrogenic construct, like the one developed in the chapter 6. Although just 
the beginning, the fact that EMD does not hinder the multilineage differentiation capacity 
of cells is promising and it will be interesting to see if/how EMD influences bone formation 
in vivo when added to our chondrogenic pellet constructs. 
CONCLUSIONS, TOWARD CLINICAL TRANSLATION  
Throughout this thesis we sought to improve TE EO. By identifying a more reproducible 
cell source we provided a better starting material with which to construct these grafts 
and by understanding the importance of COLX during chondrogenic differentiation and 
bone formation we improved our understanding of how these cells achieve EO. From a 
clinical perspective we develop a promising micropellet construct which could one day 
be optimised as an injectable bone substitute. By combining these constructs with a 
compound such as EMD it could be possible to create a construct which could improve 
both bone and soft tissue regeneration, making clinical treatment swifter and easier for 
clinicians. Although just the beginning of a long line of research, the results presented here 
are promising and with further development will highlight new ways in which researchers 
can improve bone formation output;. As these procedures become more standardised 
and routine this will drive down the cost, it requires to create TE EO constructs. As these 
avenues all merge and the field becomes more defined and understood a biologically 
relevant construct will emerge that everyone who has contributed to its advancement can 
be proud of. 
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SUMMARY
The aim of this thesis was to investigate methods to improve the generation of 
mesenchymal stem cell (MSCs) based bone grafts via the process of endochondral 
ossification (EO) and to try to further understand some of the important aspects of 
this process. As there is a clear and present need for alternative bone substitutes to be 
developed I focused on achieving bone formation via the endochondral ossification 
pathway as I believe, compared to the intramembranous pathway, it to be the more 
promising route for tissue engineered (TE) bone regeneration.  
In chapter 1 an overview of developmental endochondral bone formation is given, 
specifically focusing on the construction of the cartilage template prior to bone formation 
and the overall processes that occur. Following the establishment and hypertrophic 
differentiation of the cartilage template, the chondrogenic matrix is remodeled, invaded 
with blood vessels and mineralised. These processes must be initiated by TE grafts in 
order for bone formation to be successful. We and others have shown how this process 
can be recapitulated utilising chondrogenically differentiated MSCs, which are capable of 
inducing bone and bone marrow formation following in vivo implantation (summarised 
in chapter 1, figure 3). How TE MSC based endochondral bone constructs achieve bone 
formation is reviewed in chapter 2. Chapter 2 focused on how the TE donor components 
interact with the host to achieve bone formation and what efforts are being undertaken to 
improve knowledge about and formation of MSC endochondral bone grafts.  
We and many others have found MSC based grafts are difficult to create as the inherent 
donor variation that exists in MSCs makes reproducibility difficult. In chapter 3 I 
compared the “gold standard MSC cell source, adult bone marrow derived MSCs to a new 
cell source with improved expansion and differentiation capabilities. An easily replicated 
protocol to isolate MSCs from surplus human paediatric iliac crest material is described for 
other researchers to utilise. These cells were shown to be capable of faster proliferation, 
producing cells which more predictably underwent chondrogenic differentiation. I believe 
them to be a superior cell source compared to adult counterparts which improves the 
process of TE endochondral ossification by offering a more reliable cell source.
After identifying a more suitable starting cell population I investigated the importance of an 
extracellular matrix component, collagen type X (COLX), a collagen produced specifically 
8
Chapter  8  | 
166
by hypertrophic chondrocytes during developmental EO. The importance of COLX during 
chondrogenic differentiation of MSCs and subsequent MSC mediated EO, had yet to be 
determined. In chapter 4 I knocked down COLX expression utilising lentiviral delivered 
shRNA and showed how a significant decrease of COLX in MSCs resulted in a decreased 
chondrogenic differentiation potential. Not only was matrix formation greatly hindered 
but the secreted profile was also altered. These affects were found to be so detrimental 
that following in vivo implantation bone formation could not occur.  In this way it was 
shown that COLX is important in both proper chondrogenic differentiation of MSCs and 
subsequent bone formation. 
Also in this thesis I aimed to alter the current chondrogenic MSC format, the chondrogenic 
pellet, to create a construct which could ideally be further optimised as an injectable 
bone substitute. In chapter 5 the construction of the standard MSC pellets was altered, 
downsizing them to only 20% of the original size to create “micropellets”. In this chapter a 
straight forward protocol was described to create these micropellets and their chondrogenic 
potential after 7 and 28 days of differentiation was characterised. These micropellets were 
found to maintain their chondrogenic potential and bone forming capacity in a similar 
manner to standard pellets. With further optimisation these constructs would be ideal as 
an injectable bone substitute which would be easily applied in a clinical setting and allow 
for tailored void filling at the defect site. 
Although these MSC based constructs form bone, when a bone defect occurs it is often 
accompanied by soft tissue damage which also requires treatment. Enamel matrix 
derivative (EMD) can be utilised in ligament regeneration however it was unknown if 
this compound would have a negative effect on MSC behaviour, preventing EMD from 
being used in combination therapies to regenerate both tissue types simultaneously in 
the future. In chapter 6 we showed EMD did not prevent the trilineage differentiation 
of MSCs. This not only means the compound should not hinder the differentiation of 
MSCs in our system, but also that it should not negatively affect the endogenous MSCs 
trilineage differentiation potential. This is important as host MSCs would contribute to 
bone formation in our system. 
The findings of this thesis are more extensively discussed in chapter 7 but briefly: I 
was able to identify a more reproducible cell source for use in TE endochondral bone 
formation, improving graft formation; by identifying the importance of COLX during both 
chondrogenic differentiation and bone formation I improved our understanding of how 
MSCs achieve EO; we showed the safety of EMD for use in combinational therapies with 
MSCs; and I created and characterised a novel micropellet construct which with further 
optimisation will offer an injectable cell based bone substitute for the treatment of bone 
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defects. Although these studies are in some cases just the beginning of a long line of 
research they all move these MSC based constructs forward, towards improved bone 
regeneration.
8
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Nederlandse Samenvatting
Het doel van dit proefschrift is om inzicht te krijgen en het verbeteren van mesenchymale 
stam cel gebaseerde bot enten. Omdat er in de kliniek vraag is naar een alternatief voor 
vervangend bot heb ik mij gericht op de vorming van nieuw bot via de endochondrale 
ossificatie (EO) route, hierbij wordt kraakbeen omgevormd tot botweefsel. Ik meen 
dat EO van een kraakbeen-ent een veelbelovende optie is voor het verbeteren van de 
bot regeneratie (die na het ontstaan van een botdefect). Een ander alternatief is het 
aanmaken van bot via de intramembraneuze-route, waarbij bot wordt ontwikkeld vanuit 
bindweefselmembraan van mesenchymale stamcellen, die uiteindelijke gemineraliseerd 
worden, echter de vorming van nieuw botweefsel via de EO route is mijns inziens een 
veelbelovender optie .  
In hoofdstuk 1 wordt een overzicht geschetst van de ontwikkeling van botweefsel en 
de algehele processen die hierbij een rol spelen. Het proces waarbij kraakbeen wordt 
omgevormd tot botweefsel wordt ook wel endochondrale ossificatie genoemd. In 
hoofdstuk1 wordt de aanmaak van een sjabloon gemaakt van kraakbeen – dat uiteindelijk 
bot kan vormen – uitgelicht. Na de vorming en hypertrofe differentiatie van het kraakbeen 
sjabloon wordt de chondrogene matrix getransformeerd; er vindt minearalisatie van het 
kraakbeen plaats en er worden nieuwe bloedvaten gevormd. Dit proces wordt in werking 
gezet door gebruik te maken van de TE bot-enten.   Wij en anderen hebben laten zien dat 
dit proces kan worden hervat door gebruik te maken van chondrogeen gedifferentieerde 
MSC’s, die in staat zijn om - na in vivo implantatie - de vorming van bot en beenmerg te 
induceren (samengevat weergegeven in hoofdstuk 1, figuur 3). In hoofdstuk 2 wordt een 
overzicht gegeven over de totstandkoming van het bot met behulp van TE-MSC gebaseerde 
endochondrale bot constructen. In hoofdstuk 2 wordt in meer detail beschreven hoe de 
TE donor componenten een interactie aangaan met de gastheer om bot te vormen, en de 
pogingen die zijn ondernomen om meer inzicht te krijgen in het construeren van MSC bot 
enten. 
Wij, en vele anderen hebben ondervonden dat er veel haken en ogen zitten aan MSC 
gebaseerde enten, doordat donor variatie onafscheidelijk verbonden is aan de kwaliteit 
en reproduceerbaarheid van het kweken en differentiëren van MSCs. Hierdoor is het 
moeilijk om van iedere donor kwalitatief goed reproduceerbare constructen te kweken. 
In hoofdstuk 3 vergelijk ik de “gouden standaard” MSC cel bron (MSC’s verkregen uit 
volwassen beenmerg) met een nieuwe bron met verbeterde expansie en differentiatie 
mogelijkheden. Ik beschrijf in dit hoofdstuk een gemakkelijk reproduceerbaar protocol 
om MSC’s te isoleren vanuit chirurgisch restmateriaal afkomstig van de bekkenkam van 
kinderen. Deze cellen zijn in staat om sneller te prolifereren, alsmede beter voorspelbaar 
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chondrogeen te differentiëren.  Ik meen dat deze jonge stamcellen een betere bron zijn 
vergeleken met hun volwassen tegenhangers, waardoor het proces van TE endochondrale 
ossificatie verbeterd kan worden, immers deze stamcellen genereren een betrouwbaarder 
resultaat wat betreft de proliferatie en differentiatie capaciteiten. 
Na het identificeren van een meer geschikt start materiaal heb ik onderzocht wat 
het belang is van een extracellulaire matrix component; collageen type X (COLX), een 
collageen die specifiek wordt aangemaakt door hypertrofe chondrocyten tijdens de 
ontwikkeling van EO. Het belang van COLX tijdens de chondrogene differentiatie van 
MSC’s en de opvolgende MSC gemedieerde EO is nog onduidelijk. In hoofdstuk 4, heb 
ik de expressie van COLX door gebruik te maken van een lentiviraal shRNA construct – 
significant verlaagd in MSC’s wat resulteert in een verminderde chondrogene differentiatie. 
De vorming van matrix wordt sterk verminderd, maar ook de door de cellen gemaakte 
factoren zijn veranderd.  Deze effecten bleken zo sterk, dat na in vivo implantatie geen 
bot werd gevormd. Hieruit wordt geconcludeerd dat COLX een belangrijke rol speelt in 
zowel chondrogene differentiatie van MSC’s alsmede in de opvolgende vorming van het 
bot. 
Ook in dit proefschrift richt ik mij of de mogelijkheid om het huidige chondrogene 
MSC model, het chondrogene kraakbeen “bolletje,” aan te passen tot een injecteerbaar 
bot substituut. Hiertoe wordt, in hoofdstuk 5, de samenstelling van een standaard 
MSC kraakbeen “bolletje”, het zogenaamde MSC pellet, verkleind tot slechts 20% van 
de normale grootte; een “micropellet”. Hierna werd onderzocht hoe de chondrogene 
differentiatie verliep na 7 en 28 dagen. Deze micropellets bleken op een vergelijkbare 
manier chondrogeen te worden, wanneer ze worden vergeleken met de standaard 
pellets. Na verdere optimalisatie zouden dit type constructen ideaal zijn als injecteerbaar 
plaatsvervangend “bot”, een gemakkelijk toepasbare oplossing voor de patiënt, aangezien 
het de mogelijkheid bied van het opvullen van het botdefect met een passende, op de 
patiënt afgestelde oplossing.  
Hoewel deze MSC gebaseerde constructen bot kunnen vormen, ontstaat een bot-defect 
meestal in combinatie met schade aan het omliggende zachte weefsel, dat ook 
behandeling nodig heeft. Enamel matrix derivaten (EMD) kunnen worden gebruikt bij het 
regenereren van de gewrichtsbanden. Echter omdat het onbekend is wat het effect van 
EMD is op het karakter van de MSC’s, is het nog niet mogelijk is om EMD in combinatie 
therapieën te gebruiken waarbij zowel het bot, als de omliggende spierweefsels kunnen 
worden behandeld. In hoofdstuk 6 laten we zien dat EMD geen negatief effect heeft op 
de drie verschillende differentiaties die MSC’s kunnen ondergaan. Dit is belangrijk omdat 
MSC’s van de gastheer een belangrijk aandeel hebben in de botvorming. 
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Concluderend, in dit proefschrift heb ik een beter reproduceerbare stamcel bron gevonden 
om beter reproduceerbare enten te verkrijgen, ten behoeve van TE-gemedieerde 
endochondrale botvorming. In hoofdstuk 7 worden alle resultaten en conclusies 
uitgebreider toegelicht. Door het identificeren van de belangrijke rol van COLX tijdens 
zowel de chondrogene differentiatie alsmede de vorming van bot heb ik een beter inzicht 
verkregen in hoe MSC’s EO tot stand brengen. Wij hebben de veiligheid van EMD voor 
het gebruik van combinatie therapieën met MSC’s onderzocht. En tot slot heb ik een 
nieuw micropellet construct ontworpen en gekarakteriseerd. Na verdere optimalisatie 
bieden deze micropellets een injecteerbaar op stamcellen gebaseerd alternatief, dat 
na toediending kan worden gebruikt om plaatsvervangend bot aan te maken in een 
botdefect. Hoewel deze studies - in sommige gevallen - nog in de kinderschoenen staan 
en nog heel veel onderzoek nodig hebben, wijzen ze allemaal richting een verbeterde bot 
regeneratie met behulp van MSC’s. 
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Abbreviation index
ABG  autologous bone grafts
ACAN  aggrecan
ALP(L)  alkaline phosphatase
A-MSCs  adult mesenchymal stem cells
ANG-1  angiopoietin 1
ATMPS  advanced therapeutic medical products
BGLAP  bone gamma carboxyglutamate protein
BM  bone marrow
BMP  bone morphogenetic protein
CCN2  connective tissue growth factor
COLI  collagen type I
COLII  collagen type II
COLX/COL10A1 collagen type X
CTACK  cutaneous T-cell attracting chemokine
DC  dendritic cells
DMB  dimethylmethylene blue
H&E  haemotoxylin and eosin
DNA  deoxyribonucleic acid
ECM  extracellular matrix
EMA  european medicines agency
EMD  enamel matrix derivative
EO  endochondral ossification
FABP4  fatty acid binding protein 4
FDA  federal drug administration
FGF  fibroblast growth factor
GAG  glycoaminoglycans
GDF5  growth differentiation factor 5
HC  hypertrophic chondrocytes
hPLAP  human placental alkaline phosphatase
HSPG  heparan sulfate proteoglycans
IBSP  integrin binding sialoprotein
Ihh  indian hedgehog
IL  interleukin
IMO  intramembranous ossification
KO  knock-out
MFI  mean fluorescent intensity
MHC  major histocompatibility complex
A
Appendices  | 
176
MMP  matrix metallopeptidase
MSC  mesenchymal stem cell/marrow stromal cell
NK  natural killer cells
PBMC  peripheral blood mononuclear cells
PCR  polymerase chain reaction
PDGRa  platelet-derived growth factor receptor A
PLGA  poly(D, L-lactic-co-glycolic acid
P-MSCs  paediatric mesenchymal stem cells
PPARg  peroxisome proliferator-activated receptor gamma
PRP  platelet-rich plasma
PTHrP  parathyroid hormone-related protein
RANKL  receptor activator of nuclear factor kappa-B ligand
RISC  RNA-induced silencing complex
RNA  ribonucleic acid
RUNX2  runt-related transcription factor 2
SMCD  schmid metaphyseal chondrodysplasia disorder
SOX9  sex- determining region Y box-9 protein
TE  tissue engineering
TERM  tissue engineering and regenerative medicine
TERT-MSC telomerase reverse transcriptase mesenchymal stem cells
Tg  transgenic
TGF  transforming growth factor
TGFb  tumor growth factor beta
TIMP-1/2 tissue inhibitors of metalloproteinases ½
TNFa  tumor necrosis factor alpha
TRAP  tartrate-resistant acid phosphatase
VEGF  vascular endothelial growth factor
WNT  wingless-type MMTV integration site family
µCT  micro computed topography
µpellet  micropellet
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